ES2503739T3 - Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN - Google Patents

Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN Download PDF

Info

Publication number
ES2503739T3
ES2503739T3 ES10183481.0T ES10183481T ES2503739T3 ES 2503739 T3 ES2503739 T3 ES 2503739T3 ES 10183481 T ES10183481 T ES 10183481T ES 2503739 T3 ES2503739 T3 ES 2503739T3
Authority
ES
Spain
Prior art keywords
seq
mir
hsa
mmu
rno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10183481.0T
Other languages
English (en)
Inventor
David Brown
Lance Ford
Angie Cheng
Rich Jarvis
Mike Byrom
Dmitriy Ovcharenko
Eric Devroe
Kevin Kelnar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asuragen Inc
Original Assignee
Asuragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37570916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2503739(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asuragen Inc filed Critical Asuragen Inc
Application granted granted Critical
Publication of ES2503739T3 publication Critical patent/ES2503739T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)

Abstract

Una molécula de ácido nucleico miARN sintético que comprende una secuencia con al menos una identidad de secuencia de un 80% con la secuencia del miR-133 maduro humano para su uso en la terapia de un cáncer

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
E10183481
17-09-2014
Tabla 1
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-1-2
SEC ID Nº 1 53-73
hsa-mir-1-1
SEC ID Nº 2 46-66
hsa-let-7a-1
SEC ID Nº 3 6-27
hsa-let-7a-2
SEC ID Nº 4 5-26
hsa-let-7a-3
SEC ID Nº 5 4-25
hsa-let-7b
SEC ID Nº 6 6-27
hsa-let-7c
SEC ID Nº 7 11-32
hsa-let-7d
SEC ID Nº 8 8-28
hsa-let-7e
SEC ID Nº 9 8-28
hsa-let-7f-1
SEC ID Nº 10 7-28
hsa-let-7f-2
SEC ID Nº 11 8-29
hsa-mir-7-1
SEC ID Nº 12 24-44
hsa-mir-7-2
SEC ID Nº 13 32-52
hsa-mir-7-3
SEC ID Nº 14 31-51
hsa-let-7g
SEC ID Nº 15 5-25
hsa-let-7i
SEC ID Nº 16 6-24
hsa-mir-9-1
SEC ID Nº 17 16-38 y/o 56-76
hsa-mir-9-2
SEC ID Nº 18 16-38 y/o 54-74
hsa-mir-9-3
SEC ID Nº 19 16-38 y/o 56-76
hsa-mir-10a
SEC ID Nº 20 22-44
hsa-mir-10b
SEC ID Nº 21 27-48
hsa-mir-15a
SEC ID Nº 22 14-35
hsa-mir-15b
SEC ID Nº 23 20-41
hsa-mir-16-1
SEC ID Nº 24 14-35
hsa-mir-16-2
SEC ID Nº 25 10-31
hsa-mir-17
SEC ID Nº 26 14-37 y/o 51-70
hsa-mir-18
SEC ID Nº 27 6-27
hsa-mir-19a
SEC ID Nº 28 49-71
hsa-mir-19b-1
SEC ID Nº 29 54-76
hsa-mir-19b-2
SEC ID Nº 30 62-84
hsa-mir-20
SEC ID Nº 31 8-29
hsa-mir-21
SEC ID Nº 32 8-29
has-mir-22
SEC ID Nº 33 53-74
hsa-mir-23a
SEC ID Nº 34 45-65
hsa-mir-23b
SEC ID Nº 35 58-80
hsa-mir-24-1
SEC ID Nº 36 6-28 y/o 44-65
11
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-24-2
SEC ID Nº 37 50-71
hsa-mir-25
SEC ID Nº 38 52-73
hsa-mir-26a-1
SEC ID Nº 39 10-31
hsa-mir-26b
SEC ID Nº 40 12-32
hsa-mir-26a-2
SEC ID Nº 41 14-35
hsa-mir-27a
SEC ID Nº 42 51-72
hsa-mir-27b
SEC ID Nº 43 61-80
hsa-mir-28
SEC ID Nº 44 14-35
hsa-mir-29a
SEC ID Nº 45 41-62
hsa-mir-29b-1
SEC ID Nº 46 51-70
hsa-mir-29b-2
SEC ID Nº 47 52-71
hsa-mir-29c
SEC ID Nº 48 54-75
hsa-mir-30a
SEC ID Nº 49 47-68
hsa-mir-30c-2
SEC ID Nº 50 7-29
hsa-mir-30d
SEC ID Nº 51 6-27
hsa-mir-30b
SEC ID Nº 52 17-37
hsa-mir-30c-1
SEC ID Nº 53 17-39
hsa-mir-30e
SEC ID Nº 54 2-21
hsa-mir-31
SEC ID Nº 55 9-29
hsa-mir-32
SEC ID Nº 56 6-26
hsa-mir-33
SEC ID Nº 57 6-24
hsa-mir-34a
SEC ID Nº 58 22-43
hsa-mir-34b
SEC ID Nº 59 14-35
hsa-mir-34c
SEC ID Nº 60 13-34
hsa-mir-92-1
SEC ID Nº 61 48-69
hsa-mir-92-2
SEC ID Nº 62 48-69
hsa-mir-93
SEC ID Nº 63 12-33
hsa-mir-95
SEC ID Nº 64 49-70
hsa-mir-96
SEC ID Nº 65 9-30
hsa-mir-98
SEC ID Nº 66 2-23
hsa-mir-99a
SEC ID Nº 67 13-34
hsa-mir-99b
SEC ID Nº 68 7-28
hsa-mir-100
SEC ID Nº 69 13-34
hsa-mir-101-1
SEC ID Nº 70 47-68
12
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-101-2
SEC ID Nº 71 49-70
hsa-mir-103-2
SEC ID Nº 72 48-70
hsa-mir-103-1
SEC ID Nº 73 48-70
hsa-mir-105-1
SEC ID Nº 74 13-32
hsa-mir-105-2
SEC ID Nº 75 13-32
hsa-mir-106a
SEC ID Nº 76 13-36
hsa-mir-106b
SEC ID Nº 77 12-32
hsa-mir-107
SEC ID Nº 78 50-72
hsa-mir-122a
SEC ID Nº 79 15-37
hsa-mir-124a-1
SEC ID Nº 80 52-73
hsa-mir-124a-2
SEC ID Nº 81 61-82
hsa-mir-124a-3
SEC ID Nº 82 52-73
hsa-mir-125b-1
SEC ID Nº 83 15-36
hsa-mir-125a
SEC ID Nº 84 15-37
hsa-mir-125b-2
SEC ID Nº 85 17-38
hsa-mir-126
SEC ID Nº 86 15-35 y/o 52-72
hsa-mir-127
SEC ID Nº 87 57-78
hsa-mir-128a
SEC ID Nº 88 50-71
hsa-mir-128b
SEC ID Nº 89 52-73
hsa-mir-129-2
SEC ID Nº 90 15-35
hsa-mir-130a
SEC ID Nº 91 55-74
hsa-mir-130b
SEC ID Nº 92 51-72
hsa-mir-132
SEC ID Nº 93 59-80
hsa-mir-133a-1
SEC ID Nº 94 54-75
hsa-mir-133a-2
SEC ID Nº 95 60-81
hsa-mir-133b
SEC ID Nº 96 67-87
hsa-mir-134
SEC ID Nº 97 8-28
hsa-mir-135a-1
SEC ID Nº 98 17-39
hsa-mir-135a-2
SEC ID Nº 99 23-45
hsa-mir-135b
SEC ID Nº 100 16-37
hsa-mir-136
SEC ID Nº 101 15-37
hsa-mir-137
SEC ID Nº 102 60-81
hsa-mir-138-2
SEC ID Nº 103 10-26
hsa-mir-138-1
SEC ID Nº 104 23-39
hsa-mir-139
SEC ID Nº 105 7-24
13
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-140
SEC ID Nº 106 24-44
hsa-mir-141
SEC ID Nº 107 60-80
hsa-mir-142
SEC ID Nº 108 16-35 y/o 52-74
hsa-mir-143
SEC ID Nº 109 61-82
hsa-mir-144
SEC ID Nº 110 52-73
hsa-mir-145
SEC ID Nº 111 16-39
hsa-mir-146
SEC ID Nº 112 21-42
hsa-mir-147
SEC ID Nº 113 47-66
hsa-mir-148a
SEC ID Nº 114 44-65
hsa-mir-148b
SEC ID Nº 115 63-84
hsa-mir-149
SEC ID Nº 116 15-36
hsa-mir-150
SEC ID Nº 117 16-37
hsa-mir-151
SEC ID Nº 118 46-67
hsa-mir-152
SEC ID Nº 119 54-74
hsa-mir-153-1
SEC ID Nº 120 54-73
hsa-mir-153-2
SEC ID Nº 121 53-72
hsa-mir-154
SEC ID Nº 122 15-36
hsa-mir-155
SEC ID Nº 123 4-25
hsa-mir-181a
SEC ID Nº 124 39-61
hsa-mir-181b-1
SEC ID Nº 125 36-59
hsa-mir-181c
SEC ID Nº 126 27-48
hsa-mir-181b-2
SEC ID Nº 127 16-39
hsa-mir-182
SEC ID Nº 128 23-44 y/o 67-87
hsa-mir-183
SEC ID Nº 129 27-49
hsa-mir-184
SEC ID Nº 130 53-74
hsa-mir-185
SEC ID Nº 131 15-32
hsa-mir-186
SEC ID Nº 132 15-37
hsa-mir-187
SEC ID Nº 133 71-91
hsa-mir-188
SEC ID Nº 134 15-36
hsa-mir-190
SEC ID Nº 135 15-36
hsa-mir-191
SEC ID Nº 136 16-37
hsa-mir-192
SEC ID Nº 137 24-44
hsa-mir-193
SEC ID Nº 138 55-75
hsa-mir-194-1
SEC ID Nº 139 15-36
hsa-mir-194-2
SEC ID Nº 140 15-36
14
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-195
SEC ID Nº 141 15-35
hsa-mir-196-1
SEC ID Nº 142 7-27
hsa-mir-196-2
SEC ID Nº 143 25-45
hsa-mir-197
SEC ID Nº 144 48-69
hsa-mir-198
SEC ID Nº 145 6-24
hsa-mir-199a-1
SEC ID Nº 146 6-28 y/o 46-67
hsa-mir-199a-2
SEC ID Nº 147 31-53 y/o 69-90
hsa-mir-199b
SEC ID Nº 148 26-48
hsa-mir-200b
SEC ID Nº 149 54-77
hsa-mir-200c
SEC ID Nº 150 45-66
hsa-mir-200a
SEC ID Nº 151 54-75
hsa-mir-203
SEC ID Nº 152 65-86
hsa-mir-204
SEC ID Nº 153 33-54
hsa-mir-205
SEC ID Nº 154 34-55
hsa-mir-206
SEC ID Nº 155 53-74
hsa-mir-208
SEC ID Nº 156 44-65
hsa-mir-210
SEC ID Nº 157 66-86
hsa-mir-211
SEC ID Nº 158 26-47
hsa-mir-212
SEC ID Nº 159 71-91
hsa-mir-213
SEC ID Nº 160 24-46 y/o 64-85
hsa-mir-214
SEC ID Nº 161 71-91
hsa-mir-215
SEC ID Nº 162 27-47
hsa-mir-216
SEC ID Nº 163 19-39
hsa-mir-217
SEC ID Nº 164 35-58
hsa-mir-218-1
SEC ID Nº 165 25-45
hsa-mir-218-2
SEC ID Nº 166 25-45
hsa-mir-219-1
SEC ID Nº 167 21-41
hsa-mir-219-2
SEC ID Nº 168 19-39
hsa-mir-220
SEC ID Nº 169 23-43
hsa-mir-221
SEC ID Nº 170 65-87
hsa-mir-222
SEC ID Nº 171 69-92
hsa-mir-223
SEC ID Nº 172 68-88
hsa-mir-224
SEC ID Nº 173 8-30
hsa-mir-296
SEC ID Nº 174 14-34
hsa-mir-299
SEC ID Nº 175 7-28
15
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-301
SEC ID Nº 176 51-73
hsa-mir-302
SEC ID Nº 177 44-66
hsa-mir-320
SEC ID Nº 178 48-70
hsa-mir-321
SEC ID Nº 179 10-30
hsa-mir-323
SEC ID Nº 180 50-71
hsa-mir-324
SEC ID Nº 181 16-38 y/o 51-72
hsa-mir-326
SEC ID Nº 182 60-79
hsa-mir-328
SEC ID Nº 183 48-69
hsa-mir-330
SEC ID Nº 184 57-79
hsa-mir-331
SEC ID Nº 185 61-81
hsa-mir-335
SEC ID Nº 186 16-38
hsa-mir-337
SEC ID Nº 187 56-78
hsa-mir-338
SEC ID Nº 188 42-64
hsa-mir-339
SEC ID Nº 189 15-35
hsa-mir-340
SEC ID Nº 190 58-80
hsa-mir-342
SEC ID Nº 191 61-84
hsa-mir-345
SEC ID Nº 573 17-37
hsa-mir-346
SEC ID Nº 574 4-26
hsa-mir-367
SEC ID Nº 575 44-65
hsa-mir-368
SEC ID Nº 576 44-65
hsa-mir-369
SEC ID Nº 577 44-64
hsa-mir-370
SEC ID Nº 578 48-68
hsa-mir-371
SEC ID Nº 579 44-64
hsa-mir-372
SEC ID Nº 580 42-64
hsa-mir-373
SEC ID Nº 581 44-66
hsa-mir-374
SEC ID Nº 582 12-33
hsa-mir-375
SEC ID Nº 677 40-61
hsa-mir-376a
SEC ID Nº 678 44-64
hsa-mir-377
SEC ID Nº 679 45-66
hsa-mir-378
SEC ID Nº 680 5-26 y 44-65
hsa-mir-379
SEC ID Nº 681 6-24
hsa-mir-380
SEC ID Nº 682 5-26 y 40-61
hsa-mir-381
SEC ID Nº 683 49-70
hsa-mir-382
SEC ID Nº 684 11-32
hsa-mir-383
SEC ID Nº 685 7-28
16
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-384
SEC ID Nº 686 57-76
hsa-mir-422a
SEC ID Nº 687 11-32
hsa-mir-423
SEC ID Nº 688 53-74
hsa-mir-424
SEC ID Nº 689 11-32
hsa-mir-425
SEC ID Nº 690 55-75
hsa-mir-448
SEC ID Nº 691 71-92
hsa-mir-429
SEC ID Nº 692 51-72
hsa-mir-449
SEC ID Nº 693 16-37
hsa-mir-450-1
SEC ID Nº 694 17-38
hsa-mir-450-2
SEC ID Nº 704 22-43
hsa-mir-451
SEC ID Nº 705 17-39
hsa-mir-452
SEC ID Nº 706 17-38
hsa-mir-453
SEC ID Nº 707 43-64
hsa-mir-455
SEC ID Nº 708 16-37
hsa-mir-483
SEC ID Nº 709 48-70
hsa-mir-484
SEC ID Nº 710 2-23
hsa-mir-485
SEC ID Nº 711 9-30
hsa-mir-486
SEC ID Nº 712 4-25
hsa-mir-487
SEC ID Nº 713 49-70
hsa-mir-488
SEC ID Nº 714 14-34
hsa-mir-489
SEC ID Nº 715 51-73
hsa-mir-490
SEC ID Nº 716 76-97
hsa-mir-491
SEC ID Nº 717 16-38
hsa-mir-492
SEC ID Nº 718 30-52
hsa-mir-493
SEC ID Nº 719 16-37
hsa-mir-494
SEC ID Nº 720 48-71
hsa-mir-495
SEC ID Nº 721 50-72
hsa-mir-496
SEC ID Nº 722 61-77
hsa-mir-497
SEC ID Nº 723 24-44
hsa-mir-498
SEC ID Nº 724 34-56
hsa-mir-499
SEC ID Nº 725 33-55
hsa-mir-500
SEC ID Nº 726 52-73
hsa-mir-501
SEC ID Nº 727 14-35
hsa-mir-502
SEC ID Nº 728 1-21
hsa-mir-503
SEC ID Nº 729 6-28
17
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-504
SEC ID Nº 730 13-33
hsa-mir-505
SEC ID Nº 731 52-73
hsa-mir-506
SEC ID Nº 732 71-91
hsa-mir-507
SEC ID Nº 733 56-76
hsa-mir-508
SEC ID Nº 734 61-83
hsa-mir-509
SEC ID Nº 735 55-77
hsa-mir-510
SEC ID Nº 736 10-32
hsa-mir-511-1
SEC ID Nº 737 16-36
hsa-mir-511-2
SEC ID Nº 738 16-36
hsa-mir-512-1
SEC ID Nº 739 14-36
hsa-mir-512-2
SEC ID Nº 740 20-42
hsa-mir-513-1
SEC ID Nº 741 37-58
hsa-mir-513-2
SEC ID Nº 742 36-57
hsa-mir-514-1
SEC ID Nº 743 39-58
hsa-mir-514-2
SEC ID Nº 744 39-58
hsa-mir-514-3
SEC ID Nº 745 39-58
hsa-mir-515-1
SEC ID Nº 746 14-37
hsa-mir-515-2
SEC ID Nº 747 14-37
hsa-mir-516-1
SEC ID Nº 748 61-78
hsa-mir-516-2
SEC ID Nº 749 61-78
hsa-mir-516-3
SEC ID Nº 750 15-37
hsa-mir-516-4
SEC ID Nº 751 15-37
hsa-mir-517a
SEC ID Nº 752 15-36
hsa-mir-517b
SEC ID Nº 753 6-27
hsa-mir-517c
SEC ID Nº 754 20-41
hsa-mir-518a-1
SEC ID Nº 755 14-34
hsa-mir-518a-2
SEC ID Nº 756 15-34
hsa-mir-518b
SEC ID Nº 757 51-72
hsa-mir-518c
SEC ID Nº 758 24-46
hsa-mir-518d
SEC ID Nº 759 16-36
hsa-mir-518e
SEC ID Nº 760 54-75
hsa-mir-518f
SEC ID Nº 761 16-38
hsa-mir-519a-1
SEC ID Nº 762 15-38
hsa-mir-519a-2
SEC ID Nº 763 54-78
hsa-mir-519b
SEC ID Nº 764 13-36
18
E10183481
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-519c
SEC ID Nº 765 16-39
hsa-mir-519d
SEC ID Nº 766 54-76
hsa-mir-519e
SEC ID Nº 767 14-35
hsa-mir-520a
SEC ID Nº 768 15-35
hsa-mir-520b
SEC ID Nº 769 41-61
hsa-mir-520c
SEC ID Nº 770 16-36
hsa-mir-520d
SEC ID Nº 771 15-37
hsa-mir-520e
SEC ID Nº 772 54-74
hsa-mir-520f
SEC ID Nº 773 55-76
hsa-mir-520g
SEC ID Nº 774 55-78
hsa-mir-520h
SEC ID Nº 775 55-76
hsa-mir-521-1
SEC ID Nº 776 54-75
hsa-mir-521-2
SEC ID Nº 777 54-75
hsa-mir-522
SEC ID Nº 778 16-39
hsa-mir-523
SEC ID Nº 779 16-39
hsa-mir-524
SEC ID Nº 780 16-37
hsa-mir-525
SEC ID Nº 781 15-35
hsa-mir-526a-1
SEC ID Nº 782 15-35
hsa-mir-526a-2
SEC ID Nº 783 7-27
hsa-mir-526b
SEC ID Nº 784 14-37
hsa-mir-527
SEC ID Nº 785 14-34
ambi-mir-7100
SEC ID Nº 803
mir-526b*
SEC ID Nº 804
mir-520a*
SEC ID Nº 805
Tabla 2
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-1-1
SEC ID Nº 192 49-69
mmu-mir-1-2
SEC ID Nº 193 47-67
mmu-let-7g
SEC ID Nº 194 7-27
mmu-let-7i
SEC ID Nº 195 6-24
mmu-let-7d
SEC ID Nº 196 16-36 + 70-91
mmu-let-7a-1
SEC ID Nº 197 13-34
mmu-let-7a-2
SEC ID Nº 198 17-38
19
E10183481
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-let-7b
SEC ID Nº 199 7-28
mmu-let-7c-1
SEC ID Nº 200 16-37
mmu-let-7c-2
SEC ID Nº 201 14-35
mmu-let-7e
SEC ID Nº 202 15-35
mmu-let-7f-1
SEC ID Nº 203 8-29
mmu-let-7f-2
SEC ID Nº 204 8-29
mmu-mir-7-1
SEC ID Nº 205 24-44
mmu-mir-7-2
SEC ID Nº 206 19-39
mmu-mir-7b
SEC ID Nº 207 30-50
mmu-mir-9-2
SEC ID Nº 208 8-30 y/o 46-66
mmu-mir-9-1
SEC ID Nº 209 16-38 y/o 56-76
mmu-mir-9-3
SEC ID Nº 210 16-38 y/o 56-76
mmu-mir-10b
SEC ID Nº 211 7-28
mmu-mir-10a-1
SEC ID Nº 212 22-44
mmu-mir-10a-2
SEC ID Nº 213 22-44
mmu-mir-15b
SEC ID Nº 214 4-25
mmu-mir-15a
SEC ID Nº 215 15-36
mmu-mir-16-1
SEC ID Nº 216 16-37
mmu-mir-16-2
SEC ID Nº 217 17-38
mmu-mir-17
SEC ID Nº 218 14-37 y/o 51-70
mmu-mir-18
SEC ID Nº 219 17-38
mmu-mir-19b-2
SEC ID Nº 220 54-76
mmu-mir-19a
SEC ID Nº 221 49-71
mmu-mir-19b-1
SEC ID Nº 222 54-76
mmu-mir-20
SEC ID Nº 223 27-49
mmu-mir-21
SEC ID Nº 224 18-39
mmu-mir-22
SEC ID Nº 225 57-78
mmu-mir-23b
SEC ID Nº 226 46-68
mmu-mir-23a
SEC ID Nº 227 46-66
mmu-mir-24-1
SEC ID Nº 228 6-28 y/o 44-65
mmu-mir-24-2
SEC ID Nº 229 61-82
mmu-mir-25
SEC ID Nº 230 52-73
mmu-mir-26a-1
SEC ID Nº 231 16-37
mmu-mir-26b
SEC ID Nº 232 15-36
20
E10183481
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-26a-2
SEC ID Nº 233 14-35
mmu-mir-27b
SEC ID Nº 234 49-68
mmu-mir-27a
SEC ID Nº 235 56-76
mmu-mir-28
SEC ID Nº 236 14-35
mmu-mir-29b-1
SEC ID Nº 237 47-68
mmu-mir-29a
SEC ID Nº 238 53-74
mmu-mir-29c
SEC ID Nº 239 54-75
mmu-mir-29b-2
SEC ID Nº 240 52-73
mmu-mir-30a
SEC ID Nº 241 47-68
mmu-mir-30b
SEC ID Nº 242 2-22
mmu-mir-30e
SEC ID Nº 243 2-21
mmu-mir-30c-1
SEC ID Nº 244 17-39
mmu-mir-30c-2
SEC ID Nº 245 14-36
mmu-mir-30d
SEC ID Nº 246 12-33
mmu-mir-31
SEC ID Nº 247 28-49
mmu-mir-32
SEC ID Nº 248 6-26
mmu-mir-33
SEC ID Nº 249 6-24
mmu-mir-34c
SEC ID Nº 250 13-35
mmu-mir-34b
SEC ID Nº 251 13-35
mmu-mir-34a
SEC ID Nº 252 20-42
mmu-mir-92-2
SEC ID Nº 253 55-75
mmu-mir-92-1
SEC ID Nº 254 50-70
mmu-mir-93
SEC ID Nº 255 15-37
mmu-mir-96
SEC ID Nº 256 24-46
mmu-mir-98
SEC ID Nº 257 2-23
mmu-mir-99a
SEC ID Nº 258 6-25
mmu-mir-99b
SEC ID Nº 259 7-28
mmu-mir-100
SEC ID Nº 260 13-34
mmu-mir-101
SEC ID Nº 261 38-57
mmu-mir-101b
SEC ID Nº 262 61-82
mmu-mir-103-1
SEC ID Nº 263 52-74
mmu-mir-103-2
SEC ID Nº 264 52-74
mmu-mir-106a
SEC ID Nº 265 5-26
mmu-mir-106b
SEC ID Nº 266 12-32
mmu-mir-107
SEC ID Nº 267 52-74
21
E10183481
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-122a
SEC ID Nº 268 6-28
mmu-mir-124a-3
SEC ID Nº 269 43-64
mmu-mir-124a-1
SEC ID Nº 270 52-73
mmu-mir-124a-2
SEC ID Nº 271 61-82
mmu-mir-125a
SEC ID Nº 272 6-28
mmu-mir-125b-2
SEC ID Nº 273 7-28
mmu-mir-125b-1
SEC ID Nº 274 15-36
mmu-mir-126
SEC ID Nº 275 9-29 y/o 46-66
mmu-mir-127
SEC ID Nº 276 43-64
mmu-mir-128a
SEC ID Nº 277 44-65
mmu-mir-128b
SEC ID Nº 278 48-69
mmu-mir-129-1
SEC ID Nº 279 6-27
mmu-mir-129-2
SEC ID Nº 280 15-36
mmu-mir-130a
SEC ID Nº 281 42-61
mmu-mir-130b
SEC ID Nº 282 51-72
mmu-mir-132
SEC ID Nº 283 42-63
mmu-mir-133a-1
SEC ID Nº 284 44-65
mmu-mir-133a-2
SEC ID Nº 285 60-81
mmu-mir-133b
SEC ID Nº 286 67-87
mmu-mir-134
SEC ID Nº 287 7-27
mmu-mir-135a-1
SEC ID Nº 288 17-39
mmu-mir-135b
SEC ID Nº 289 16-37
mmu-mir-135a-2
SEC ID Nº 290 23-45
mmu-mir-136
SEC ID Nº 291 5-27
mmu-mir-137
SEC ID Nº 292 46-67
mmu-mir-138-2
SEC ID Nº 293 2-18
mmu-mir-138-1
SEC ID Nº 294 23-39
mmu-mir-139
SEC ID Nº 295 7-24
mmu-mir-140
SEC ID Nº 296 7-27
mmu-mir-141
SEC ID Nº 297 49-69
mmu-mir-142
SEC ID Nº 298 4-23 y/o 40-61
mmu-mir-143
SEC ID Nº 299 40-61
mmu-mir-144
SEC ID Nº 300 43-64
mmu-mir-145
SEC ID Nº 301 7-30
mmu-mir-146
SEC ID Nº 302 6-27
22
E10183481
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-148a
SEC ID Nº 303 61-82
mmu-mir-149
SEC ID Nº 304 4-25
mmu-mir-150
SEC ID Nº 305 6-27
mmu-mir-151
SEC ID Nº 306 43-63
mmu-mir-152
SEC ID Nº 307 47-67
mmu-mir-153
SEC ID Nº 308 44-63
mmu-mir-154
SEC ID Nº 309 6-27
mmu-mir-155
SEC ID Nº 310 4-25
mmu-mir-181a
SEC ID Nº 311 7-29
mmu-mir-181b-1
SEC ID Nº 312 12-35
mmu-mir-181c
SEC ID Nº 313 17-38
mmu-mir-181b-2
SEC ID Nº 314 16-39
mmu-mir-182
SEC ID Nº 315 7-28
mmu-mir-183
SEC ID Nº 316 6-28
mmu-mir-184
SEC ID Nº 317 45-66
mmu-mir-185
SEC ID Nº 318 7-24
mmu-mir-186
SEC ID Nº 319 7-29
mmu-mir-187
SEC ID Nº 320 40-61
mmu-mir-188
SEC ID Nº 321 6-27
mmu-mir-190
SEC ID Nº 322 6-27
mmu-mir-191
SEC ID Nº 323 7-28
mmu-mir-192
SEC ID Nº 324 14-31
mmu-mir-193
SEC ID Nº 325 41-61
mmu-mir-194-1
SEC ID Nº 326 7-28
mmu-mir-194-2
SEC ID Nº 327 16-37
mmu-mir-195
SEC ID Nº 328 1-21
mmu-mir-196-1
SEC ID Nº 329 24-44
mmu-mir-196-2
SEC ID Nº 330 16-36
mmu-mir-199a-1
SEC ID Nº 331 6-28 y/o 45-66
mmu-mir-199a-2
SEC ID Nº 332 31-53 y/o 69-90
mmu-mir-199b
SEC ID Nº 333 26-48
mmu-mir-200b
SEC ID Nº 334 45-67
mmu-mir-200a
SEC ID Nº 335 54-75
mmu-mir-200c
SEC ID Nº 336 46-67
mmu-mir-201
SEC ID Nº 337 6-26
23
E10183481
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-202
SEC ID Nº 338 45-66
mmu-mir-203
SEC ID Nº 339 49-69
mmu-mir-204
SEC ID Nº 340 6-28
mmu-mir-205
SEC ID Nº 341 7-28
mmu-mir-206
SEC ID Nº 342 46-67
mmu-mir-207
SEC ID Nº 343 52-74
mmu-mir-208
SEC ID Nº 344 50-71
mmu-mir-210
SEC ID Nº 345 66-86
mmu-mir-211
SEC ID Nº 346 26-47
mmu-mir-212
SEC ID Nº 347 56-76
mmu-mir-213
SEC ID Nº 348 14-36 y/o 54-75
mmu-mir-214
SEC ID Nº 349 71-91
mmu-mir-215
SEC ID Nº 350 30-50
mmu-mir-216
SEC ID Nº 351 7-27
mmu-mir-217
SEC ID Nº 352 34-57
mmu-mir-218-2
SEC ID Nº 353 25-45
mmu-mir-219-1
SEC ID Nº 354 21-41
mmu-mir-219-2
SEC ID Nº 355 19-39
mmu-mir-221
SEC ID Nº 356 60-81
mmu-mir-222
SEC ID Nº 357 49-71
mmu-mir-223
SEC ID Nº 358 68-88
mmu-mir-224
SEC ID Nº 359 8-30
mu-miR-290
SEC ID Nº 360 15-37
mmu-mir-291
SEC ID Nº 361 14-35 y/o 50-72
mmu-mir-292
SEC ID Nº 362 12-33 y/o 51-73
mmu-mir-293
SEC ID Nº 363 48-69
mmu-mir-294
SEC ID Nº 364 51-72
mmu-mir-295
SEC ID Nº 365 43-65
mmu-mir-296
SEC ID Nº 366 13-33
mmu-mir-297-1
SEC ID Nº 367 15-35
mmu-mir-297-2
SEC ID Nº 368 36-56
mmu-mir-298
SEC ID Nº 369 11-32
mmu-mir-299
SEC ID Nº 370 7-28
mmu-mir-300
SEC ID Nº 371 51-72
mmu-mir-301
SEC ID Nº 372 51-73
24
E10183481
17-09-2014
(continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-302
SEC ID Nº 373 44-66
mmu-mir-320
SEC ID Nº 374 48-70
mmu-mir-321
SEC ID Nº 375 10-30
mmu-mir-323
SEC ID Nº 376 50-71
mmu-mir-324
SEC ID Nº 377 18-40 y/o 53-74
mmu-mir-325
SEC ID Nº 378 16-38
mmu-mir-326
SEC ID Nº 379 60-80
mmu-mir-328
SEC ID Nº 380 61-82
mmu-mir-329
SEC ID Nº 381 61-82
mmu-mir-330
SEC ID Nº 382 61-83
mmu-mir-331
SEC ID Nº 383 61-81
mmu-mir-337
SEC ID Nº 384 61-83
mmu-mir-338
SEC ID Nº 385 61-83
mmu-mir-339
SEC ID Nº 386 16-36
mmu-mir-340
SEC ID Nº 387 61-83
mmu-mir-341
SEC ID Nº 388 61-81
mmu-mir-342
SEC ID Nº 389 61-84
mmu-mir-344
SEC ID Nº 390 61-83
mmu-mir-345
SEC ID Nº 391 16-36
mmu-mir-346
SEC ID Nº 392 16-38
mmu-mir-350
SEC ID Nº 393 61-84
mmu-mir-351
SEC ID Nº 583 16-39
mmu-mir-370
SEC ID Nº 584 48-70
mmu-mir-376a
SEC ID Nº 585 44-64
mmu-mir-376b
SEC ID Nº 586 51-72
mmu-mir-380
SEC ID Nº 587 40-61
mmu-mir-409
SEC ID Nº 588 47-69
mmu-mir-410
SEC ID Nº 589 50-71
mmu-mir-411
SEC ID Nº 590 56-78
mmu-mir-412
SEC ID Nº 591 50-72
mmu-mir-425
SEC ID Nº 695 54-74
mmu-mir-429
SEC ID Nº 696 51-72
mmu-mir-448
SEC ID Nº 697 72-93
mmu-mir-449
SEC ID Nº 698 16-37
mmu-mir-450
SEC ID Nº 699 17-38
25
imagen10
E10183481
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-9-2
SEC ID Nº 409 16-38
rno-mir-10a
SEC ID Nº 410 22-44
rno-mir-10b
SEC ID Nº 411 26-47
rno-mir-15b
SEC ID Nº 412 20-41
rno-mir-16
SEC ID Nº 413 17-38
rno-mir-17
SEC ID Nº 414 14-37
rno-mir-18
SEC ID Nº 415 17-38
rno-mir-19b-1
SEC ID Nº 416 54-76
rno-mir-19b-2
SEC ID Nº 417 62-84
rno-mir-19a
SEC ID Nº 418 49-71
rno-mir-20
SEC ID Nº 419 16-38 y/o 52-72
rno-mir-21
SEC ID Nº 420 18-39
rno-mir-22
SEC ID Nº 421 57-78
rno-mir-23a
SEC ID Nº 422 46-66
rno-mir-23b
SEC ID Nº 423 58-80
rno-mir-24-1
SEC ID Nº 424 44-65
rno-mir-24-2
SEC ID Nº 425 61-82
rno-mir-25
SEC ID Nº 426 52-73
mo-mir-26a
SEC ID Nº 427 16-37
rno-mir-26b
SEC ID Nº 428 15-36
rno-mir-27b
SEC ID Nº 429 61-80
rno-mir-27a
SEC ID Nº 430 56-76
rno-mir-28
SEC ID Nº 431 14-35
rno-mir-29b-2
SEC ID Nº 432 52-73
rno-mir-29a
SEC ID Nº 433 53-74
rno-mir-29b-1
SEC ID Nº 434 51-72
rno-mir-29c
SEC ID Nº 435 54-75
rno-mir-30c-1
SEC ID Nº 436 17-39
rno-mir-30e
SEC ID Nº 437 2-21
rno-mir-30b
SEC ID Nº 438 16-36
rno-mir-30d
SEC ID Nº 439 12-33
rno-mir-30a
SEC ID Nº 440 47-68
rno-mir-30c-2
SEC ID Nº 441 14-36
rno-mir-31
SEC ID Nº 442 28-49
rno-mir-32
SEC ID Nº 443 6-26
27
E10183481
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-33
SEC ID Nº 444 6-24
rno-mir-34b
SEC ID Nº 445 13-35
rno-mir-34c
SEC ID Nº 446 13-35
rno-mir-34a
SEC ID Nº 447 20-42
rno-mir-92-1
SEC ID Nº 448 48-68
rno-mir-92-2
SEC ID Nº 449 55-75
rno-mir-93
SEC ID Nº 450 15-37
rno-mir-96
SEC ID Nº 451 24-46
rno-mir-98
SEC ID Nº 452 2-23
rno-mir-99a
SEC ID Nº 453 13-34
rno-mir-99b
SEC ID Nº 454 7-28
rno-mir-100
SEC ID Nº 455 13-34
rno-mir-101b
SEC ID Nº 456 61-82
rno-mir-101
SEC ID Nº 457 47-68
rno-mir-103-2
SEC ID Nº 458 52-74
rno-mir-103-1
SEC ID Nº 459 52-74
rno-mir-106b
SEC ID Nº 460 12-32
rno-mir-107
SEC ID Nº 461 52-74
rno-mir-122a
SEC ID Nº 462 15-37
rno-mir-124a-3
SEC ID Nº 463 52-73
rno-mir-124a-1
SEC ID Nº 464 52-73
rno-mir-124a-2
SEC ID Nº 465 61-82
rno-mir-125a
SEC ID Nº 466 15-37
rno-mir-125b-1
SEC ID Nº 467 15-36
rno-mir-125b-2
SEC ID Nº 468 17-38
rno-mir-126
SEC ID Nº 469 9-29 y/o 46-66
rno-mir-127
SEC ID Nº 470 57-78
mo-mir-128a
SEC ID Nº 471 50-71
mo-mir-128b
SEC ID Nº 472 52-73
rno-mir-129-2
SEC ID Nº 473 19-40 y/o 61-82
rno-mir-129-1
SEC ID Nº 474 6-27
rno-mir-130a
SEC ID Nº 475 55-74
rno-mir-130b
SEC ID Nº 476 51-72
rno-mir-132
SEC ID Nº 477 59-80
rno-mir-133a
SEC ID Nº 478 53-74
28
E10183481
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-134
SEC ID Nº 479 8-28
rno-mir-135b
SEC ID Nº 480 16-37
rno-mir-135a
SEC ID Nº 481 23-45
rno-mir-136
SEC ID Nº 482 15-37
rno-mir-137
SEC ID Nº 483 60-81
rno-mir-138-2
SEC ID Nº 484 9-25
mo-mir-138-1
SEC ID Nº 485 23-39
rno-mir-139
SEC ID Nº 486 7-24
rno-mir-140
SEC ID Nº 487 23-43 y/o 61-84
rno-mir-141
SEC ID Nº 488 59-79
rno-mir-142
SEC ID Nº 489 16-35 y/o 52-74
rno-mir-143
SEC ID Nº 490 60-81
rno-mir-144
SEC ID Nº 491 50-71
rno-mir-145
SEC ID Nº 492 16-39
rno-mir-146
SEC ID Nº 493 17-38
rno-mir-148b
SEC ID Nº 494 61-82
rno-mir-150
SEC ID Nº 495 16-37
rno-mir-151
SEC ID Nº 496 16-37 y/o 50-71
rno-mir-152
SEC ID Nº 497 53-73
rno-mir-153
SEC ID Nº 498 53-72
rno-mir-154
SEC ID Nº 499 15-36
rno-mir-181c
SEC ID Nº 500 24-45
rno-mir-181a
SEC ID Nº 501 39-61
rno-mir-181b-1
SEC ID Nº 502 36-59
rno-mir-181b-2
SEC ID Nº 503 15-38
rno-mir-183
SEC ID Nº 504 27-49
rno-mir-184
SEC ID Nº 505 47-68
rno-mir-185
SEC ID Nº 506 14-31
rno-mir-186
SEC ID Nº 507 15-37
rno-mir-187
SEC ID Nº 508 66-86
rno-mir-190
SEC ID Nº 509 15-36
rno-mir-191
SEC ID Nº 510 15-36
rno-mir-192
SEC ID Nº 511 24-44
rno-mir-193
SEC ID Nº 512 54-74
rno-mir-194-1
SEC ID Nº 513 15-36
29
E10183481
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-194-2
SEC ID Nº 514 15-36
rno-mir-195
SEC ID Nº 515 15-35
rno-mir-196
SEC ID Nº 516 25-45
rno-mir-199a
SEC ID Nº 517 31-53
rno-mir-200c
SEC ID Nº 518 46-67
rno-mir-200a
SEC ID Nº 519 54-75
rno-mir-200b
SEC ID Nº 520 54-77
rno-mir-203
SEC ID Nº 521 52-73
rno-mir-204
SEC ID Nº 522 33-54
rno-mir-205
SEC ID Nº 523 33-54
rno-mir-206
SEC ID Nº 524 51-72
rno-mir-208
SEC ID Nº 525 50-71
rno-mir-210
SEC ID Nº 526 66-86
rno-mir-211
SEC ID Nº 527 26-47
rno-mir-212
SEC ID Nº 528 72-92
rno-mir-213
SEC ID Nº 529 55-76
rno-mir-214
SEC ID Nº 530 71-91
rno-mir-216
SEC ID Nº 531 19-39
rno-mir-217
SEC ID Nº 532 32-55
rno-mir-218-2
SEC ID Nº 533 25-45
rno-mir-218-1
SEC ID Nº 534 25-45
rno-mir-219-1
SEC ID Nº 535 21-41
rno-mir-219-2
SEC ID Nº 536 19-39
rno-mir-221
SEC ID Nº 537 65-87
rno-mir-222
SEC ID Nº 538 62-85
rno-mir-223
SEC ID Nº 539 68-88
rno-mir-290
SEC ID Nº 540 14-36
rno-mir-291
SEC ID Nº 541 14-35 y/o 50-72
rno-mir-292
SEC ID Nº 542 12-33 y/o 51-73
rno-mir-296
SEC ID Nº 543 13-33
rno-mir-297
SEC ID Nº 544 26-48
rno-mir-298
SEC ID Nº 545 11-32
rno-mir-299
SEC ID Nº 546 7-28
rno-mir-300
SEC ID Nº 547 51-72
rno-mir-301
SEC ID Nº 548 61-85
30
E10183481
17-09-2014
(continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-320
SEC ID Nº 549 48-70
rno-mir-321
SEC ID Nº 550 10-30
rno-mir-322
SEC ID Nº 551 61-80
rno-mir-323
SEC ID Nº 552 50-71
rno-mir-324
SEC ID Nº 553 16-38 y/o 51-72
rno-mir-325
SEC ID Nº 554 16-38
rno-mir-326
SEC ID Nº 555 60-80
rno-mir-328
SEC ID Nº 556 48-69
rno-mir-329
SEC ID Nº 557 61-82
rno-mir-330
SEC ID Nº 558 60-82
rno-mir-3 31
SEC ID Nº 559 61-81
rno-mir-333
SEC ID Nº 560 16-35
rno-mir-336
SEC ID Nº 561 16-36
rno-mir-337
SEC ID Nº 562 60-82
rno-mir-338
SEC ID Nº 563 41-63
rno-mir-339
SEC ID Nº 564 16-36
rno-mir-341
SEC ID Nº 565 61-81
rno-mir-342
SEC ID Nº 566 61-84
rno-mir-344
SEC ID Nº 567 61-83
rno-mir-345
SEC ID Nº 568 16-36
rno-mir-346
SEC ID Nº 569 16-38
rno-mir-349
SEC ID Nº 570 61-82
rno-mir-350
SEC ID Nº 571 61-84
rno-mir-351
SEC ID Nº 572 16-39
rno-mir-352
SEC ID Nº 592 61-81
rno-mir-421
SEC ID Nº 593 10-30
rno-mir-429
SEC ID Nº 700 53-74
rno-mir-448
SEC ID Nº 701 72-93
rno-mir-449
SEC ID Nº 702 16-37
rno-mir-450
SEC ID Nº 703 17-38
rno-mir-451
SEC ID Nº 801 17-38
rno-mir-483
SEC ID Nº 802 45-67
Se entiende que un miARN se deriva de secuencias genómicas de un gen. A este respecto, el término “gen” se utiliza por simplicidad para referirse a la secuencia genómica que codifica el precursor de miARN de un determinado
31
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50

Claims (1)

  1. imagen1
    imagen2
ES10183481.0T 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN Active ES2503739T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62717104P 2004-11-12 2004-11-12
US627171P 2004-11-12
US64963405P 2005-02-03 2005-02-03
US649634P 2005-02-03
US68373605P 2005-05-23 2005-05-23
US683736P 2005-05-23

Publications (1)

Publication Number Publication Date
ES2503739T3 true ES2503739T3 (es) 2014-10-07

Family

ID=37570916

Family Applications (13)

Application Number Title Priority Date Filing Date
ES10183543.7T Active ES2503743T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183525.4T Active ES2503740T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183490.1T Active ES2534301T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183481.0T Active ES2503739T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183589.0T Active ES2534303T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183567.6T Active ES2534302T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183534.6T Active ES2503741T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183538.7T Active ES2503742T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183596.5T Active ES2534304T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183462.0T Active ES2534300T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183456.2T Active ES2503738T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183611.2T Active ES2503765T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183577.5T Active ES2507544T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES10183543.7T Active ES2503743T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183525.4T Active ES2503740T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183490.1T Active ES2534301T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Family Applications After (9)

Application Number Title Priority Date Filing Date
ES10183589.0T Active ES2534303T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183567.6T Active ES2534302T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183534.6T Active ES2503741T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183538.7T Active ES2503742T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183596.5T Active ES2534304T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183462.0T Active ES2534300T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183456.2T Active ES2503738T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183611.2T Active ES2503765T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183577.5T Active ES2507544T3 (es) 2004-11-12 2005-11-14 Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Country Status (11)

Country Link
US (25) US8173611B2 (es)
EP (21) EP2808389A1 (es)
JP (11) JP2008519606A (es)
AU (1) AU2005333165B2 (es)
CA (7) CA2587189A1 (es)
DK (1) DK2302055T3 (es)
ES (13) ES2503743T3 (es)
HK (1) HK1204656A1 (es)
PL (1) PL2302055T3 (es)
SI (1) SI2302055T1 (es)
WO (1) WO2006137941A2 (es)

Families Citing this family (382)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
JP5435864B2 (ja) * 2004-05-28 2014-03-05 アシュラジェン インコーポレイテッド マイクロｒｎａに関与する方法および組成物
WO2006027776A1 (en) * 2004-09-07 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US20090186353A1 (en) * 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US7825229B2 (en) * 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US7642348B2 (en) * 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
DK2302055T3 (da) * 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
US8592384B2 (en) 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
CN101535331B (zh) * 2005-04-29 2013-01-30 洛克菲勒大学 人类微小rna以及用于抑制人类微小rna的方法
EP1904111A4 (en) * 2005-06-03 2009-08-19 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR DECREASING MICROARN EXPRESSION FOR THE TREATMENT OF NEOPLASIA
JP5489459B2 (ja) * 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
WO2007033023A2 (en) 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
JP2009511482A (ja) * 2005-10-05 2009-03-19 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｗｗｏｘ遺伝子、同じものを含むベクター、および癌の治療における使用
BRPI0619755A2 (pt) 2005-12-12 2011-10-18 Univ North Carolina micrornas que regulam a proliferação e diferenciação de células musculares
ES2554531T3 (es) * 2006-01-05 2015-12-21 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
AU2016203848B2 (en) * 2006-01-05 2017-12-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ES2465600T3 (es) * 2006-01-05 2014-06-06 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos del páncreas
EP2586454B1 (en) 2006-01-05 2014-10-08 The Ohio State University Research Foundation MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
WO2007109236A2 (en) 2006-03-20 2007-09-27 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
CN102851291B (zh) 2006-04-03 2016-03-09 斯特拉有限责任公司 包含抗微小rna反义寡核苷酸的药物组合物
CN101657547B (zh) 2006-07-13 2016-04-27 俄亥俄州立大学研究基金会 用于诊断和治疗结肠癌相关疾病的基于微小rna的方法和组合物
EP2434017A3 (en) 2006-08-01 2012-09-05 Board of Regents of the University of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
EP2046970B2 (en) † 2006-08-04 2020-04-29 Dublin City University A method of producing recombinant biological products
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
JPWO2008029790A1 (ja) * 2006-09-04 2010-01-21 協和発酵キリン株式会社 新規核酸
CA2663962A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
US8071292B2 (en) 2006-09-19 2011-12-06 The Ohio State University Research Foundation Leukemia diagnostic methods
EP2086590A4 (en) 2006-10-24 2011-04-06 Univ Leland Stanford Junior MODULATION OF A T-CELL SIGNALING THRESHOLD AND THE SENSITIVITY OF T-CELLS AGAINST ANTIGENE
CA2667617A1 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
WO2008073921A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-126 regulated genes and pathways as targets for therapeutic intervention
EP2104737B1 (en) * 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
EP2104734A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-20 regulated genes and pathways as targets for therapeutic intervention
AU2007333107A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
CN101627121A (zh) * 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008088858A2 (en) * 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
EP2109687B1 (en) 2007-01-31 2014-06-04 The Ohio State University Research Foundation Micro-rna-based methods for the treatment of acute myeloid leukemia
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
CA2699418A1 (en) * 2007-02-27 2008-09-04 Moshe Oren Composition and methods for modulating cell proliferation and cell death
WO2008107901A2 (en) * 2007-03-07 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
WO2008115387A2 (en) * 2007-03-15 2008-09-25 University Hospitals Of Cleveland Screening, diagnosing, treating and prognosis of pathophysiologic states by rna regulation
WO2008116267A1 (en) 2007-03-26 2008-10-02 Crc For Asthma And Airways Ltd Therapeutic targets and molecules
US20100273172A1 (en) * 2007-03-27 2010-10-28 Rosetta Genomics Ltd. Micrornas expression signature for determination of tumors origin
US20090117562A1 (en) 2007-04-09 2009-05-07 Valerie Wailin Hu Method and kit for diagnosing Autism using gene expression profiling
EP2142659A4 (en) * 2007-04-30 2010-06-09 Univ Ohio State Res Found METHOD FOR THE DISTINCTION OF PANCREATIC CANCER OF NORMAL IMMERSION SPECTRUM FUNCTIONS AND CHRONIC IMMERSION IMAGING IGNITION
EP1990414A1 (en) * 2007-05-10 2008-11-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means for treating inflammatory diseases, autoimmune diseases and cancer
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008147974A1 (en) 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
AU2008262252B2 (en) 2007-06-08 2013-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US20090227533A1 (en) * 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US8053186B2 (en) * 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
US20090012031A1 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
KR20100057022A (ko) 2007-07-31 2010-05-28 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 마이오신 발현 및 근섬유 동일성을 제어하는 마이크로-ｒｎａｓ
EP2808398A1 (en) * 2007-07-31 2014-12-03 The Ohio State University Research Foundation Methods for reverting methylation by targeting DNMT3A and DNMT3B
US8440636B2 (en) 2007-07-31 2013-05-14 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates fibrosis and uses thereof
US7812003B2 (en) * 2007-08-02 2010-10-12 Safe Stephen H Antisense microRNA and uses therefor
ES2627059T3 (es) 2007-08-03 2017-07-26 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
WO2009021235A2 (en) * 2007-08-09 2009-02-12 The Regents Of The University Of Colorado Methods and compositions for treating cancer
CA2733676A1 (en) 2007-08-10 2009-02-19 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CN101376910B (zh) * 2007-08-27 2012-01-11 中国科学院上海生命科学研究院 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
EP2183393B1 (en) * 2007-09-06 2014-06-11 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
EP2198050A1 (en) * 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009044895A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 標的遺伝子の発現を抑制する組成物
WO2009044899A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
CN101821391B (zh) 2007-10-04 2016-04-27 桑塔里斯制药公司 微小聚体
CN103937876B (zh) * 2007-10-11 2016-08-17 俄亥俄州立大学研究基金会 用于诊断和治疗食管腺癌的方法和组合物
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
US8911998B2 (en) 2007-10-26 2014-12-16 The Ohio State University Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
WO2009058907A2 (en) 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
CA2701298A1 (en) * 2007-11-05 2009-05-14 Kci Licensing Inc. Identification of tissue for debridement
NZ585209A (en) 2007-11-09 2012-08-31 Univ Texas Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
ITRM20070595A1 (it) * 2007-11-15 2009-05-16 Univ Roma Mirna e sirna e loro uso in terapia
WO2009066967A2 (en) * 2007-11-23 2009-05-28 Panagene Inc. Microrna antisense pnas, compositions comprising the same, and methods for using and evaluating the same
JP2011505143A (ja) * 2007-11-30 2011-02-24 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
KR101325186B1 (ko) 2008-01-23 2013-11-07 (주)바이오니아 이중가닥 ｍｉＲＮＡ를 유효성분으로 포함하는 항암제
JP5116026B2 (ja) 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
CA2708661A1 (en) * 2008-01-27 2009-07-30 Rosetta Genomics Ltd. Methods and compositions for diagnosing complications of pregnancy
EP2260110B1 (en) * 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
WO2009108853A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
JP2011517932A (ja) * 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト慢性リンパ球性白血病（ｃｃｌ）と関連するマイクロｒｎａシグネチャーおよびその使用
CN104031984A (zh) * 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2265291B1 (en) * 2008-03-17 2016-10-19 The Board of Regents of The University of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
WO2009120712A2 (en) 2008-03-24 2009-10-01 New York University Compositions and methods for diagnosing and treating melanoma
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
EP2279267A4 (en) * 2008-03-27 2012-01-18 Vascular Biosciences Inc METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES
CN102046810B (zh) * 2008-04-07 2014-11-19 康奈尔研究基金公司 血管生成抑制
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
CA2723716A1 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
EP2285960B1 (en) 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
US20110178159A1 (en) * 2008-05-08 2011-07-21 Hua Gu Inhibitory rnas that regulate hematopoietic cells
WO2009147658A2 (en) * 2008-06-02 2009-12-10 New York University Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
US8927207B2 (en) * 2008-06-05 2015-01-06 Research Foundation Of State University Of New York miRNAs as therapeutic targets in cancer
US8900627B2 (en) * 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
WO2009148631A1 (en) * 2008-06-06 2009-12-10 The Board Of Trustees Of The Leland Stanford Junior University Role of mirna in t cell leukemia
CN102149827B (zh) 2008-06-11 2014-08-20 由卫生与公众服务部代表的美利坚合众国政府 MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途
US8252534B2 (en) * 2008-06-12 2012-08-28 City Of Hope Micro RNAs and their methods of use for the treatment and diagnosis of schizophrenia and schizophrenia spectrum disorders
US20110077168A1 (en) * 2008-06-17 2011-03-31 Nitzan Rosenfeld Methods for distinguishing between specific types of lung cancers
WO2009153774A2 (en) * 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
AU2009264170A1 (en) 2008-06-27 2009-12-30 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Prediction of antiviral therapy response
BRPI0913657A2 (pt) 2008-07-01 2020-08-04 Monsanto Technology Llc constructos de dna recombinante e métodos para a modulação da expressão de um gene-alvo
WO2010001632A1 (ja) * 2008-07-03 2010-01-07 国立大学法人神戸大学 関節リウマチ関連マイクロｒｎａ
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
KR101042052B1 (ko) * 2008-08-05 2011-06-16 사회복지법인 삼성생명공익재단 항-ｍｉｃｒｏＲＮＡ를 포함하는 고형암 예방 또는 치료용조성물
US20110280861A1 (en) * 2008-08-08 2011-11-17 Massachusetts Institute Of Technology Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
WO2010019446A1 (en) * 2008-08-09 2010-02-18 University Of Iowa Research Foundation Nucleic acid aptamers
CA2733556A1 (en) * 2008-08-11 2010-02-18 The Board Of Regents Of The University Of Texas System A micro-rna that promotes vascular integrity and uses thereof
AU2009281969A1 (en) * 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-RNA-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
US20120149586A1 (en) * 2008-08-15 2012-06-14 Scottsdale Healthcare Methods of predicting the risk of recurrence of cancer
EP2326730B1 (en) * 2008-08-19 2014-03-19 Maine Institute For Human Genetics And Health Micro rna (mirna) and neurofibromatosis type 1 : a role in diagnosis and therapy
WO2010033818A2 (en) 2008-09-19 2010-03-25 Immune Disease Institute, Inc. Mirna targets
EP2364367B8 (en) * 2008-11-10 2017-08-23 Battelle Memorial Institute Method utilizing microrna for detecting interstitial lung disease
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
US8734759B2 (en) 2008-12-05 2014-05-27 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
AU2009322137B2 (en) * 2008-12-05 2015-09-10 Whitehead Institute For Biomedical Research Compositions and methods relating to miR-31
EP2208785A1 (en) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
WO2010084488A1 (en) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
US9493832B2 (en) 2009-02-02 2016-11-15 Cepheid Methods of detecting sepsis
RU2515926C2 (ru) * 2009-02-04 2014-05-20 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Двойное нацеливание нп mir-208 и mir 499 в лечении заболеваний сердца
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
US20100311815A1 (en) * 2009-02-23 2010-12-09 The Regents Of The University Of Michigan Mir-101 cancer markers
JP2012518997A (ja) * 2009-02-26 2012-08-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法
WO2010107397A1 (en) * 2009-03-19 2010-09-23 Agency For Science, Technology And Research Modulators of apoptosis and the uses thereof
US20120087992A1 (en) * 2009-03-20 2012-04-12 Jingfang Ju miRNAS AS THERAPEUTIC TARGETS IN CANCER
WO2010117829A2 (en) 2009-03-31 2010-10-14 The United States Of America As Represented By The Secretary Department Of Health And Human Services Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome
WO2010120969A1 (en) * 2009-04-15 2010-10-21 Board Of Regents, The University Of Texas System Targeting of the mir-30 family and let-7 family as a treatment for heart disease
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
CN102421917B (zh) * 2009-04-29 2014-07-09 阿姆斯特丹大学学术医学中心 对抗、预防和/或测定心力衰竭或心力衰竭的风险的工具和方法
WO2010127186A1 (en) 2009-04-30 2010-11-04 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
WO2010129860A2 (en) * 2009-05-08 2010-11-11 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
US20130177624A1 (en) * 2009-05-08 2013-07-11 David Brian Corry Mirna expression in allergic disease
US8924232B2 (en) * 2009-05-11 2014-12-30 Koninklijke Philips N.V. Device and method for comparing molecular signatures
KR20120047214A (ko) * 2009-05-20 2012-05-11 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근경색 후 리모델링 및 심부전에 관련된 마이크로―ｒｎａ의 확인
CN102459598B (zh) 2009-05-20 2016-06-01 Eth苏黎世公司 用于代谢紊乱的靶向微小rna
WO2010136846A1 (en) * 2009-05-25 2010-12-02 Carola Ponzetto Differentiation therapy for sarcomas
DK2435583T3 (da) * 2009-05-25 2014-09-29 Universit Degli Studi Di Roma La Sapienza miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
US10421961B2 (en) 2009-06-10 2019-09-24 Exostem Biotec Ltd Methods, systems, and compositions for neuronal differentiation of multipotent stromal cells
US20100322909A1 (en) 2009-06-17 2010-12-23 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Th1-associated micrornas and their use for tumor immunotherapy
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
WO2011012136A1 (en) * 2009-07-28 2011-02-03 Exiqon A/S A method for classifying a human cell sample as cancerous
FR2948687B1 (fr) * 2009-07-29 2015-09-04 Centre Nat Rech Scient Utilisation de microarn pour le traitement de pathologies respiratoires chroniques
WO2011014697A1 (en) * 2009-07-31 2011-02-03 The Translational Genomics Research Institute Methods of assessing a risk of cancer progression
WO2011017408A1 (en) * 2009-08-05 2011-02-10 The Ohio State University Research Foundation Anti-mir-1 therapy for wound healing
CN102762731B (zh) * 2009-08-05 2018-06-22 库尔纳公司 通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
EP2283846A1 (en) 2009-08-12 2011-02-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. miRNA compounds for treatment of prostate carcinoma
US8796238B2 (en) 2009-09-17 2014-08-05 Sigma-Aldrich Co. Llc Short RNA mimetics
WO2011047147A1 (en) * 2009-10-14 2011-04-21 Baylor College Of Medicine Microrna mirna-31 as a therapeutic approach for the treatment of cancer
US8841273B2 (en) * 2009-10-28 2014-09-23 Board Of Regents, The University Of Texas System Methods and compositions for anti-EGFR treatment
EP3118334A1 (en) 2009-11-04 2017-01-18 DiamiR, LLC Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
JP2013511559A (ja) * 2009-11-24 2013-04-04 ザ ユニバーシティ オブ ウェスタン オーストラリア 上皮成長因子受容体リガンドのモジュレーション
EP2327783A1 (en) * 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20120315640A1 (en) 2009-12-21 2012-12-13 Hidetoshi Tahara Senescence marker, method for evaluating senescence inhibitor, and cancer inhibitor
WO2011084815A1 (en) * 2009-12-21 2011-07-14 Board Of Trustees Of Southern Illinois University Inhibition of ubc9-mediated cancer cell invasion and metastasis
EP2518144B1 (en) * 2009-12-21 2015-08-05 Hiroshima University Aging marker, method for evaluating aging inhibitor, and cancer inhibitor
WO2011079299A1 (en) * 2009-12-23 2011-06-30 The George Washington University Compositions and methods for identifying autism spectrum disorders
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
US8846631B2 (en) 2010-01-14 2014-09-30 Regulus Therapeutics Inc. MicroRNA compositions and methods
WO2011091209A1 (en) * 2010-01-21 2011-07-28 North Carolina State University Small molecule modifiers of microrna mir-122
JP2011188849A (ja) * 2010-02-18 2011-09-29 Okayama Univ 抗腫瘍効果を有するｍｉＲ−７発現プラスミド
US8841269B2 (en) * 2010-02-23 2014-09-23 Creighton University Polynucleotides for use in treating and diagnosing cancers
EP2542678B1 (en) * 2010-03-04 2017-04-12 InteRNA Technologies B.V. A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
WO2011111715A1 (ja) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
AU2011237729B2 (en) 2010-04-05 2014-04-03 Prognosys Biosciences, Inc. Spatially encoded biological assays
DK2561078T3 (en) 2010-04-23 2019-01-14 Cold Spring Harbor Laboratory NEW STRUCTURALLY DESIGNED SHRNAs
WO2011150420A1 (en) * 2010-05-28 2011-12-01 Baylor College Of Medicine Modified gold nanoparticles for therapy
EP2576785A4 (en) 2010-06-04 2014-12-24 Univ Texas REGULATION OF METABOLISM BY MIR-378
EP2580327B1 (en) * 2010-06-09 2014-01-22 Chanel Parfums Beauté Inhibitors of micro-rnas for use for preventing and/or attenuating skin ageing and/or for hydrating skin
NZ704322A (en) * 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CN103189511B (zh) * 2010-07-12 2016-10-12 国立大学法人鸟取大学 利用siRNA导入的新型hiPSC制作法
US8580513B2 (en) * 2010-07-20 2013-11-12 Trustees Of Dartmouth College Methods for determining response to neoadjuvant therapy and survival using MicroRNA-10b
WO2012012716A2 (en) 2010-07-23 2012-01-26 Regulus Therapeutics, Inc. Targeting micrornas for the treatment of fibrosis
US10385314B2 (en) 2010-08-16 2019-08-20 Exostem Biotec Ltd. Methods of generating oligodendrocytes and cell populations comprising same
WO2012023132A1 (en) * 2010-08-16 2012-02-23 Brainstem Biotech Ltd. Methods of generating oligodendrocytes and cell populations comprising same
RU2013104137A (ru) 2010-08-17 2014-09-27 Университэ Де Женева Изоформы bard1 при раке легкого и колоректальном раке и их применение
US8642342B2 (en) 2010-08-19 2014-02-04 Regents Of The University Of Michigan Methods for regulating neural differentiation
EP2426217A1 (en) * 2010-09-03 2012-03-07 Centre National de la Recherche Scientifique (CNRS) Analytical methods for cell free nucleic acids and applications
US9006195B2 (en) * 2010-09-13 2015-04-14 California Institute Of Technology Regulation of hematopoietic stem cell functions through microRNAs
CN103221542A (zh) * 2010-09-27 2013-07-24 萨班哲大学 miRNA用于诊断、预防、治疗和追踪涉及巨自噬异常的疾病的用途
US8933051B2 (en) 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
WO2012065049A1 (en) * 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
EP2638912A4 (en) 2010-11-12 2015-01-21 Nat Univ Corp Ehime Univ COMPOSITIONS WITH AN ANTISENSE OLIGONUCLEOTIDE AGAINST MICRO RNA
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
JP6155194B2 (ja) 2010-11-17 2017-06-28 インターペース ダイアグノスティックス リミテッド ライアビリティ カンパニー 良性甲状腺新生物と悪性甲状腺新生物を区別するためのバイオマーカーとしてのｍｉＲＮＡ
US11344505B1 (en) 2010-12-01 2022-05-31 Gowey Research Group, Pllc Herbal formulations of carnivorous plants and methods for treating inflammation
US11414663B2 (en) 2010-12-01 2022-08-16 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
EP3214185A1 (en) * 2010-12-01 2017-09-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the outcome of colon cancer by analysing mirna expression
US10744151B1 (en) * 2010-12-01 2020-08-18 Gowey Research Group PLLC Micro-RNA profiling, compositions, and methods of treating diseases
US10758578B2 (en) 2010-12-01 2020-09-01 Gowey Research Group PLLC Herbal formulations of carnivorous plants and methods for treating inflammation
CA2817371A1 (en) 2010-12-15 2012-06-21 Miragen Therapeutics Microrna inhibitors comprising locked nucleotides
EP2658972A4 (en) * 2010-12-15 2015-05-06 Medimmune Llc MELANOMA TREATMENT
EP2654801B1 (en) * 2010-12-20 2017-11-01 Agency For Science, Technology And Research Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
WO2012106586A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
CA2844596A1 (en) * 2011-02-07 2012-08-16 Biomirna Holdings Ltd. Micro-rna biomarkers and methods of using same
CN103561750A (zh) 2011-03-07 2014-02-05 俄亥俄州立大学 通过microRNA-155(miR-155)诱导的增变活性使炎症与癌症关联
EP3792359A1 (en) * 2011-03-30 2021-03-17 Transine Therapeutics Limited Functional nucleic acid molecule and use thereof
EP2691548B1 (en) * 2011-03-31 2017-11-22 University of Houston Microrna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
WO2012140234A1 (en) 2011-04-13 2012-10-18 Vib Vzw Modulation of mirna in diseases with aberrant angiogenesis
AU2012245628B2 (en) 2011-04-18 2016-09-22 Diamir, Llc Methods of using miRNA from bodily fluids for early detection and monitoring of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
WO2012145743A1 (en) * 2011-04-22 2012-10-26 University Of Houston Microrna-140-5p as a tumor suppressor and sensitizing agent for chemotherapy
UA115652C2 (uk) 2011-04-25 2017-12-11 Реґюлус Терап'Ютікс Інк. Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
EE201100037A (et) * 2011-05-16 2012-12-17 Tartu Ülikool MikroRNAde kasutamine biomarkeritena ja sihtm„rkidena raku proliferatiivsete omaduste m?jutamiseks ja meetod ning komplekt nende ekspressioonitaseme tuvastamiseks
US20140221648A1 (en) * 2011-06-27 2014-08-07 Galderma Research & Developement Th17 differentiation markers for acne and uses thereof
BR112013033617B1 (pt) 2011-06-27 2021-10-26 Galderma Research & Development Uso de mrna, método para o diagnóstico de acne, métodos para o monitoramento da progressão ou variação de acne e da eficácia de um tratamento para tratar acne, e de triagem in vitro para a identificação de inibidores de diferenciação de células th17
US8747860B2 (en) * 2011-07-06 2014-06-10 Institute For Systems Biology Methods and compositions to modulate antiviral and immune activity responses
EP2740266A1 (en) 2011-08-01 2014-06-11 Thomson Licensing Telepresence communications system and method
CA2844012C (en) 2011-08-04 2021-03-16 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
US8987224B2 (en) 2011-08-05 2015-03-24 Baylor College Of Medicine MicroRNA-198 as a tumor suppressor in pancreatic cancer
US20140199402A1 (en) 2011-08-12 2014-07-17 Alexander Schmidt Novel compounds for the treatment of inflammatory bowel disease
WO2013032962A2 (en) * 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease
US9434944B2 (en) 2011-08-31 2016-09-06 University Of Zurich Modulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
CA2844577A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
EP2584040A1 (en) 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
WO2013065791A1 (ja) * 2011-11-02 2013-05-10 公立大学法人大阪市立大学 遺伝子発現抑制用二本鎖核酸分子
JP2015504847A (ja) * 2011-11-30 2015-02-16 シーダーズ−サイナイ メディカル センター 前立腺癌骨転移および薬剤耐性肺癌を治療するためのマイクロｒｎａｍｉｒ−４０９−５ｐ、ｍｉｒ−３７９、およびｍｉｒ−１５４＊の標的化
CN105722993A (zh) * 2011-12-01 2016-06-29 俄亥俄州国家创新基金会 与结肠直肠癌的nsaid化学预防相关的材料和方法
JP2015501645A (ja) * 2011-12-10 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法
CN104619353A (zh) * 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
EP2844745A2 (en) 2012-02-22 2015-03-11 Brainstem Biotec Ltd. Generation of neural stem cells and motor neurons
EP3401393B1 (en) 2012-02-22 2020-02-19 Exostem Biotec Ltd Micrornas for the generation of astrocytes
WO2013133863A1 (en) 2012-03-09 2013-09-12 Thomson Licensing Distributed control of synchronized content
AU2013251696B2 (en) 2012-04-25 2018-11-15 Sanofi MicroRNA compounds and methods for modulating miR-21 activity
US9598694B2 (en) 2012-05-02 2017-03-21 The Board Of Regents Of The University Of Texas System Micro-RNAs involved in macular degeneration
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
CN104603272B (zh) * 2012-07-06 2017-11-07 宝生物工程株式会社 能够产生腺伴随病毒载体的细胞
EP2877186A4 (en) 2012-07-27 2016-08-31 Agency Science Tech & Res METHOD FOR PROMOTING WOUND HEALING
JP6340366B2 (ja) 2012-07-31 2018-06-06 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 運動ニューロン疾患を診断および処置する方法
EP2703498B1 (en) * 2012-08-29 2015-01-14 Chanel Parfums Beauté Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing
EP2702998A1 (en) 2012-08-31 2014-03-05 IMBA-Institut für Molekulare Biotechnologie GmbH Therapeutic and diagnostic miRNA regulator in kidney disease
WO2014043159A1 (en) * 2012-09-11 2014-03-20 New York University Sera based mirnas as non-invasive biomarkers in melanoma
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP3901280A1 (en) 2012-10-17 2021-10-27 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US9944991B2 (en) 2012-11-02 2018-04-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
US9340787B2 (en) * 2012-11-15 2016-05-17 Yale University Compositions and methods of using micro RNAs
US20140243387A1 (en) * 2012-12-18 2014-08-28 Icahn School Of Medicine At Mount Sinai Methods for improving cardiac contractility
DK2963125T3 (da) * 2013-02-15 2020-10-12 Univ Nat Corp Tokyo Medical & Dental Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret
WO2014164753A1 (en) * 2013-03-11 2014-10-09 Emory University Methods and compositions for managing vascular conditions
US9006200B2 (en) * 2013-03-13 2015-04-14 Asbestos Diseases Research Foundation MicroRNA-based approach to treating malignant pleural mesothelioma
US20160032383A1 (en) * 2013-03-15 2016-02-04 Albert Einstein College Of Medicine Of Yeshiva University PANEL OF microRNA BIOMARKERS IN HEALTHY AGING
EP2968567A2 (en) 2013-03-15 2016-01-20 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
WO2014151835A1 (en) 2013-03-15 2014-09-25 Miragen Therapeutics, Inc Locked nucleic acid inhibitor of mir-145 and uses thereof
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
WO2014168616A1 (en) 2013-04-10 2014-10-16 Thomson Licensing Tiering and manipulation of peer's heads in a telepresence system
JP2016169158A (ja) * 2013-06-14 2016-09-23 北海道公立大学法人 札幌医科大学 大腸癌を治療および／または診断するための組成物ならびにその利用
GB201310755D0 (en) * 2013-06-17 2013-07-31 Ucl Business Plc Therapy
EP3011691B1 (en) 2013-06-20 2022-11-30 InterDigital CE Patent Holdings System and method to assist synchronization of distributed play out of control
AU2014302702A1 (en) 2013-06-24 2015-12-17 Mirna Therapeutics, Inc. Biomarkers of miR-34 activity
EP4234716A3 (en) 2013-06-25 2023-12-06 Prognosys Biosciences, Inc. Methods for determining spatial patterns of biological targets in a sample
US9862943B1 (en) * 2013-06-27 2018-01-09 California Institute Of Technology Long noncoding RNAs and cell reprogramming and differentiation
WO2015020122A1 (ja) * 2013-08-08 2015-02-12 国立大学法人 大阪大学 尿路上皮癌の診断または治療剤
KR101566586B1 (ko) * 2013-08-21 2015-11-16 서울대학교산학협력단 miRNA를 표적으로 하는 뇌전증 또는 발작 관련 질환의 예방 또는 치료용 약학 조성물 및 방법
EP3049522A2 (en) * 2013-09-26 2016-08-03 Friedrich Miescher Institute for Biomedical Research Tools and methods using mirna 182, 96 and/or 183 for treating pathologies
US20150089870A1 (en) * 2013-10-01 2015-04-02 Wayne State University Population control of invasive plant species and restoration of native plant communities
KR101598070B1 (ko) * 2013-10-17 2016-02-26 한국과학기술연구원 마약 중독 예방 및 치료용 약제학적 조성물
ES2836133T3 (es) * 2013-10-28 2021-06-24 Icahn School Med Mount Sinai Composiciones y métodos para modular la excitabilidad neuronal y el comportamiento motor
KR101559131B1 (ko) * 2013-11-18 2015-10-07 한국원자력의학원 ｍｉＲＮＡ를 포함하는 방사선 민감성 증진용 조성물
CA2931082C (en) 2013-11-18 2024-01-23 Diamir, Llc Methods of using mirnas from bodily fluids for detection and monitoring of parkinson's disease (pd)
EP3178943B1 (en) 2013-12-17 2018-10-03 Csir A method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
WO2015099188A1 (ja) * 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
CA2935022A1 (en) * 2013-12-27 2015-07-02 Bonac Corporation Artificial match-type mirna for controlling gene expression and use therefor
US10125365B2 (en) 2014-02-05 2018-11-13 Yeda Research And Development Co. Ltd. Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2015133637A1 (ja) * 2014-03-07 2015-09-11 国立大学法人京都大学 マイクロｒｎａ封入ナノ粒子及びその医薬用途
EP3126496A1 (en) 2014-04-01 2017-02-08 Mirna Therapeutics, Inc. Microrna dosing regimens
EP3409794B1 (en) * 2014-05-02 2021-03-24 Ruprecht-Karls-Universität Heidelberg Circulating mirnas as early detection marker and prognostic marker
ES2850281T3 (es) * 2014-06-26 2021-08-26 Icahn School Med Mount Sinai Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
EP3170706A4 (en) * 2014-07-15 2018-03-28 Mitsuba Corporation Brushless wiper motor
LU92499B1 (en) 2014-07-16 2016-01-18 Univ Muenster Wilhelms Mirna 320a as biomarker for inflammatory bowel disease
ES2558262B2 (es) 2014-08-01 2016-07-14 Universidad Católica De Valencia "San Vicente Mártir" Método de diagnóstico de fibromialgia basado en microRNAs
US9487783B2 (en) 2014-08-07 2016-11-08 Regulus Therapeutics Inc. Targeting microRNAs for metabolic disorders
US20170298352A1 (en) * 2014-09-30 2017-10-19 Research Institute at Nationwide Children's Hospit al Compositions and methods for treating hepatic fibrosis
EP3239297B1 (en) * 2014-12-27 2021-03-10 Bonac Corporation Naturally occuring mirna for controlling gene expression, and use of same
JP2018503646A (ja) 2015-01-20 2018-02-08 ミラゲン セラピューティクス， インコーポレイテッド ｍｉＲ−９２阻害剤およびその使用
GB201504772D0 (en) 2015-03-20 2015-05-06 Univ Aston Preeclampsia
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
CA2982146A1 (en) 2015-04-10 2016-10-13 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
EP3284822A1 (en) * 2015-04-17 2018-02-21 The University of Tokyo Therapeutic agent for eye disease
WO2016183414A1 (en) * 2015-05-14 2016-11-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing granulomatous diseases
WO2016190899A1 (en) * 2015-05-23 2016-12-01 Beem Alan M H Pri-mirna libraries and methods for making and using pri-mirna libraries
US10858627B2 (en) 2015-07-30 2020-12-08 Regents Of The University Of Minnesota Regulation of mesodermal specification
CN108367017A (zh) * 2015-08-13 2018-08-03 索马根尼科斯公司 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
WO2017032776A1 (en) * 2015-08-21 2017-03-02 Universitätsklinikum Jena Human micrornas for treatment of malignant tumours
US11285168B2 (en) 2015-09-28 2022-03-29 National University Corporation Chiba University Method for suppressing tumors by miR-200 family inhibition
EP3356553A1 (en) 2015-09-29 2018-08-08 The Research Institute at Nationwide Children's Hospital Methods for detecting hepatic fibrosis and responsiveness to therapy
JP6666002B2 (ja) * 2015-10-07 2020-03-13 国立大学法人京都大学 Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
JP2018537983A (ja) * 2015-12-10 2018-12-27 ウニヴェルズィテート・フューア・ボーデンクルトゥーア・ウィーン 骨折および骨障害の診断および治療のための組成物および方法
EP3181698A1 (en) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 as stem cell marker
CA3001536A1 (en) 2015-12-28 2017-07-06 Riken Compositions for use in recovering or ameliorating deterioration of physiological functions due to aging
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
CN105543225A (zh) * 2016-01-07 2016-05-04 华东师范大学 miR143及其诱导物LTA在制备抑制痤疮炎症药物中的应用
US10771508B2 (en) 2016-01-19 2020-09-08 Nadejda Sarmova Systems and methods for establishing a virtual shared experience for media playback
CA3016592A1 (en) 2016-03-04 2017-09-08 Rhode Island Hospital Targeting microrna for cancer treatment
US11149313B2 (en) 2016-03-21 2021-10-19 Diamir, Llc Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases
CN109477090B (zh) * 2016-04-14 2022-03-22 e-NA生物科技公司 微小rna-143衍生物
WO2017192601A1 (en) * 2016-05-02 2017-11-09 University Of Massachusetts T cell differentiation and function regulation
CN109562140B (zh) * 2016-06-03 2023-01-03 霍夫耳科研究所 用于内耳感觉毛细胞再生/替换的联合疗法
EP3533868A4 (en) * 2016-10-31 2019-12-11 Gifu University DOUBLE-STRANDED NUCLEIC ACID MOLECULE AND USE THEREOF
JP7130639B2 (ja) 2016-11-01 2022-09-05 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク ５－ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用
CN107058470B (zh) * 2016-11-03 2020-09-01 中国人民解放军陆军军医大学 一种通过联合miR-136和miR-4791预测急性高山病发病风险的诊断试剂盒
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
CN107223203B (zh) 2017-04-19 2018-07-06 深圳市汇顶科技股份有限公司 光强检测方法、装置及智能终端
WO2018199231A1 (ja) * 2017-04-28 2018-11-01 一丸ファルコス株式会社 プラセンタ抽出物
WO2018204829A1 (en) * 2017-05-04 2018-11-08 University Of Maryland, Baltimore Methods for preventing neural tube defects in diabetic pregnancy
EP3624825A4 (en) * 2017-05-19 2021-03-10 Georgia State University Research Foundation, Inc. RECOMBINANT ONCOLYTIC VIRUS
US20210139895A1 (en) * 2017-06-16 2021-05-13 Prostemics Co., Ltd. Pharmaceutical composition for preventing or treating cancer
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
WO2019116234A1 (en) 2017-12-12 2019-06-20 Nestec S.A. Methods for determining microbiome ribosomal rna composition changes
KR20200131287A (ko) * 2018-03-14 2020-11-23 베스 이스라엘 데코니스 메디칼 센터 마이크로-rna 22의 억제제
WO2019195765A1 (en) * 2018-04-06 2019-10-10 University Of Massachusetts Mlk-regulated micrornas in angiogenesis and tumor development
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US20220145392A1 (en) * 2019-03-11 2022-05-12 Ochsner Health System Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터
US20220251552A1 (en) * 2019-03-25 2022-08-11 The Trustees Of The University Of Pennsylvania Regenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US10844380B1 (en) 2019-06-17 2020-11-24 Biorchestra Co., Ltd. Uses for prevention or treatment of brain diseases using microrna
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
WO2021091611A1 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
US12037585B2 (en) 2019-12-23 2024-07-16 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation
ES2946357T3 (es) 2019-12-23 2023-07-17 10X Genomics Inc Métodos para el análisis espacial usando ligación con molde de ARN
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US12076701B2 (en) 2020-01-31 2024-09-03 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
US20230210883A1 (en) * 2020-03-13 2023-07-06 Duke University Compositions for the treatment of nash and associated disorders and methods of using same
CN115916999A (zh) 2020-04-22 2023-04-04 10X基因组学有限公司 用于使用靶向rna耗竭进行空间分析的方法
WO2021237087A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Spatial analysis to detect sequence variants
EP4414459A3 (en) 2020-05-22 2024-09-18 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
AU2021283184A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
AU2021283174A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Nucleic acid library methods
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
EP4162074B1 (en) 2020-06-08 2024-04-24 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
EP4165207B1 (en) 2020-06-10 2024-09-25 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
EP4172362B1 (en) 2020-06-25 2024-09-18 10X Genomics, Inc. Spatial analysis of dna methylation
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
CN112190592B (zh) * 2020-08-25 2022-03-11 苏州市立医院(北区) miRNA在制备防治骨关节炎药物的应用、miRNA高表达的外泌体和应用
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
WO2022076774A2 (en) * 2020-10-08 2022-04-14 The Trustees Of Columbia University In The City Of New York Treatment and detection of liver fibrosis and liver disease using microrna
CN112375823B (zh) * 2020-10-22 2022-09-16 上海交通大学医学院附属瑞金医院 miRNA抑制剂在制备治疗和/或预防淋巴瘤的药物中的应用
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
EP4121555A1 (en) 2020-12-21 2023-01-25 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
EP4301870A1 (en) 2021-03-18 2024-01-10 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
WO2022256503A1 (en) 2021-06-03 2022-12-08 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
WO2022272269A1 (en) * 2021-06-22 2022-12-29 The Curators Of The University Of Missouri Multianalyte biomarkers for lung cancer
WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
WO2023118546A2 (en) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
WO2024108031A2 (en) * 2022-11-16 2024-05-23 University Of Notre Dame Du Lac Mirna cocktail for treatment and prevention of fibrosis
KR102583230B1 (ko) * 2023-03-16 2023-09-27 재단법인 전남바이오산업진흥원 뇌경색 예방 또는 치료용 조성물

Family Cites Families (497)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2007A (en) * 1841-03-16 Improvement in the mode of harvesting grain
US1529202A (en) 1924-07-16 1925-03-10 Joseph H Miller Festooning machine for carrying paper and the like
GB1529202A (en) 1976-02-20 1978-10-18 Ciba Geigy Ag Spectral sensitising dyes
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
JPS55116259A (en) 1979-03-01 1980-09-06 Fuji Photo Film Co Ltd Microimmunoassay method
JPS5745460A (en) 1980-09-02 1982-03-15 Fuji Photo Film Co Ltd Inspection sheet for measuring trace component and inspecting method using said sheet
EP0047472B1 (en) 1980-09-02 1985-04-24 Fuji Photo Film Co., Ltd. Method for immunochemical measurement of trace components
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4849513A (en) 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US5011769A (en) 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US4876187A (en) 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US4910300A (en) 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4816571A (en) 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
GB8803000D0 (en) 1988-02-10 1988-03-09 Ekins Roger Philip Determination of ambient concentrations of several analytes
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US4999290A (en) 1988-03-31 1991-03-12 The Board Of Regents, The University Of Texas System Detection of genomic abnormalities with unique aberrant gene transcripts
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5708154A (en) 1989-02-24 1998-01-13 City Of Hope RNA-DNA hybrid molecules of nucleic acid
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
GB8920097D0 (en) 1989-09-06 1989-10-18 Ici Plc Amplification processes
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
EP0942000B1 (en) 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5188934A (en) 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5872232A (en) 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5965364A (en) 1990-10-09 1999-10-12 Benner; Steven Albert Method for selecting functional deoxyribonucleotide derivatives
WO1992007095A1 (en) 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
US6369209B1 (en) * 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
IL103674A0 (en) 1991-11-19 1993-04-04 Houston Advanced Res Center Method and apparatus for molecule detection
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5260191A (en) 1992-01-30 1993-11-09 Agracetus, Inc. Method for diagnosing tumors
JPH07504087A (ja) 1992-02-12 1995-05-11 クロマジェン　インク 蛍光性ｎ−ヌクレオシド及び蛍光性ｎ−ヌクレオシド構造類似体の応用
US5652099A (en) 1992-02-12 1997-07-29 Conrad; Michael J. Probes comprising fluorescent nucleosides and uses thereof
DE4204650C1 (es) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
DE69333650T2 (de) 1992-02-19 2006-01-12 The Public Health Research Institute Of The City Of New York, Inc. Neue anordnungn von oligonukleotiden und ihr nutzen zum sortieren, isolieren, sequenzieren und manipulieren von nukleinsäuren
US5262311A (en) 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
DE69332665T2 (de) 1992-03-11 2003-11-27 Dana-Farber Cancer Institute, Inc. Methode um mrna zu klonieren
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
GB9208545D0 (en) 1992-04-21 1992-06-03 Gatsby Charitable Foundation T Virus resistant plants
US5428148A (en) 1992-04-24 1995-06-27 Beckman Instruments, Inc. N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
ATE398679T1 (de) 1992-07-07 2008-07-15 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
HUT70467A (en) 1992-07-27 1995-10-30 Pioneer Hi Bred Int An improved method of agrobactenium-mediated transformation of cultvred soyhean cells
US5438131A (en) 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5580726A (en) 1994-04-29 1996-12-03 Geron Corporation Method and Kit for enhanced differential display
US5767259A (en) 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
AU8102694A (en) 1993-11-17 1995-06-06 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
US5610287A (en) 1993-12-06 1997-03-11 Molecular Tool, Inc. Method for immobilizing nucleic acid molecules
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
JPH09508800A (ja) 1994-02-14 1997-09-09 スミスクライン・ビーチャム・コーポレイション 差次的発現遺伝子の同定法
DE4406524A1 (de) 1994-02-28 1995-08-31 Boehringer Mannheim Gmbh 3'-RNA-Markierung mit Terminaler Transferase
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5574146A (en) 1994-08-30 1996-11-12 Beckman Instruments, Inc. Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US5554744A (en) 1994-09-23 1996-09-10 Hybridon, Inc. Method for loading solid supports for nucleic acid synthesis
US6096314A (en) 1994-10-07 2000-08-01 Yeda Research And Development Co. Ltd. Peptides and pharmaceutical compositions comprising them
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
WO1996029430A1 (en) 1995-03-17 1996-09-26 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
US5801155A (en) 1995-04-03 1998-09-01 Epoch Pharmaceuticals, Inc. Covalently linked oligonucleotide minor grove binder conjugates
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
DE19518505A1 (de) 1995-05-19 1996-11-21 Max Planck Gesellschaft Verfahren zur Genexpressionsanalyse
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5637683A (en) 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US5658734A (en) 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5871697A (en) 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US6418382B2 (en) 1995-10-24 2002-07-09 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US20040142895A1 (en) 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
JP2002515738A (ja) 1996-01-23 2002-05-28 アフィメトリックス，インコーポレイティド 核酸分析法
US5837196A (en) 1996-01-26 1998-11-17 The Regents Of The University Of California High density array fabrication and readout method for a fiber optic biosensor
US5670663A (en) 1996-02-14 1997-09-23 Regents Of The University Of California Recovery of taxanes from conifers
US6020481A (en) 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
US6458530B1 (en) 1996-04-04 2002-10-01 Affymetrix Inc. Selecting tag nucleic acids
JP3898228B2 (ja) 1996-04-12 2007-03-28 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク 検出プローブ、キット及びアッセイ
US5800996A (en) 1996-05-03 1998-09-01 The Perkin Elmer Corporation Energy transfer dyes with enchanced fluorescence
US5863727A (en) 1996-05-03 1999-01-26 The Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5847162A (en) 1996-06-27 1998-12-08 The Perkin Elmer Corporation 4, 7-Dichlororhodamine dyes
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
CA2257109C (en) 1996-06-04 2009-10-06 University Of Utah Research Foundation Monitoring hybridization during pcr
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
GB9618050D0 (en) 1996-08-29 1996-10-09 Cancer Res Campaign Tech Global amplification of nucleic acids
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
ATE438719T1 (de) 1997-03-07 2009-08-15 Siemens Healthcare Diagnostics Spezifischer marker für prostatakrebs
CA2254785A1 (en) 1997-03-10 1998-09-17 Japan Tobacco Inc. Antisense base sequences
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
NO972006D0 (no) 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6262252B1 (en) 1997-05-19 2001-07-17 Mirus, Inc. Single-step method for labeling nucleic acids with mustard or aziridine labeling reagents
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
ATE319856T1 (de) 1997-06-13 2006-03-15 Affymetrix Inc A Delaware Corp Verfahren zur erkennung von genpolymorphismen und allelexpression unter verwendung von sondenchips
US6008379A (en) 1997-10-01 1999-12-28 The Perkin-Elmer Corporation Aromatic-substituted xanthene dyes
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
US6355421B1 (en) 1997-10-27 2002-03-12 Boston Probes, Inc. Methods, kits and compositions pertaining to PNA molecular beacons
WO1999023256A1 (en) 1997-10-30 1999-05-14 Cold Spring Harbor Laboratory Probe arrays and methods of using probe arrays for distinguishing dna
US5936087A (en) 1997-11-25 1999-08-10 The Perkin-Elmer Corporation Dibenzorhodamine dyes
US6238869B1 (en) 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6232066B1 (en) 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
US6458533B1 (en) 1997-12-19 2002-10-01 High Throughput Genomics, Inc. High throughput assay system for monitoring ESTs
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6121058A (en) 1998-01-02 2000-09-19 Intel Corporation Method for removing accumulated solder from probe card probing features
US6087102A (en) 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6269846B1 (en) 1998-01-13 2001-08-07 Genetic Microsystems, Inc. Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays
US5942398A (en) 1998-02-26 1999-08-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glutx and uses thereof
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
EP1071753A2 (en) 1998-04-20 2001-01-31 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6037129A (en) 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
FR2780059B1 (fr) 1998-06-17 2002-10-11 Bio Merieux Procede de marquage d'un acide ribonucleique et fragments d'arn marques ainsi obtenus
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
GB9815799D0 (en) 1998-07-21 1998-09-16 Pharmagene Lab Limited Quantitative analysis of gene expression
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
US6140054A (en) 1998-09-30 2000-10-31 University Of Utah Research Foundation Multiplex genotyping using fluorescent hybridization probes
DE69929542T2 (de) 1998-10-27 2006-09-14 Affymetrix, Inc., Santa Clara Komplexitätsmanagement und analyse genomischer dna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9904991D0 (en) 1999-03-05 1999-04-28 Univ Nottingham Genetic screening
EP1161439B1 (en) 1999-03-18 2010-04-21 Exiqon A/S Xylo-lna analogues
US6383752B1 (en) 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
US6103576A (en) * 1999-04-13 2000-08-15 Microchip Technology Incorporated Dielectric layer of a memory cell having a stacked oxide sidewall and method of fabricating same
ES2283298T3 (es) 1999-05-04 2007-11-01 Santaris Pharma A/S Analogos de l-ribo-lna.
US6638717B2 (en) 1999-05-19 2003-10-28 Aventis Pharmaceuticals, Inc. Microarray-based subtractive hybridzation
CA2371922C (en) 1999-05-24 2012-03-27 Introgen Therapeutics, Inc. Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
CA2377385A1 (en) 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
WO2000075356A1 (en) 1999-06-04 2000-12-14 Lin Shi Lung Rna polymerase chain reaction
US6964847B1 (en) 1999-07-14 2005-11-15 Packard Biosciences Company Derivative nucleic acids and uses thereof
US6201112B1 (en) 1999-07-22 2001-03-13 Agilent Technologies Inc. Method for 3′ end-labeling ribonucleic acids
US7005261B1 (en) 1999-07-29 2006-02-28 British Biocell International Limited Method for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter
US6140500A (en) 1999-09-03 2000-10-31 Pe Corporation Red-emitting [8,9]benzophenoxazine nucleic acid dyes and methods for their use
US6511832B1 (en) 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US20020094546A1 (en) 1999-10-07 2002-07-18 Shimkets Richard A. Growth factor polypeptides and nucleic acids encoding same
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6528254B1 (en) 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US6191278B1 (en) 1999-11-03 2001-02-20 Pe Corporation Water-soluble rhodamine dyes and conjugates thereof
US6458382B1 (en) 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
US6435245B1 (en) 1999-11-18 2002-08-20 Pitney Bowes Inc. System for folding and tabbing sheets
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
WO2001038580A2 (en) 1999-11-26 2001-05-31 Curagen Corporation Nucleic acid probe arrays
US6383749B2 (en) 1999-12-02 2002-05-07 Clontech Laboratories, Inc. Methods of labeling nucleic acids for use in array based hybridization assays
US7205105B2 (en) 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
EP1257664A4 (en) 2000-01-28 2006-04-05 Althea Technologies Inc METHOD FOR THE ANALYSIS OF GENE EXPRESSION
WO2002081628A2 (en) 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US6447723B1 (en) 2000-03-13 2002-09-10 Packard Instrument Company, Inc. Microarray spotting instruments incorporating sensors and methods of using sensors for improving performance of microarray spotting instruments
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US20020037540A1 (en) 2000-03-23 2002-03-28 Shujath Ali Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP1268818A2 (en) 2000-03-24 2003-01-02 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
US6787335B2 (en) 2000-03-27 2004-09-07 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating mammary gland cancer
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
AU2001251084A1 (en) 2000-03-29 2001-10-08 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
US20020068307A1 (en) 2000-03-30 2002-06-06 Jason Pluta Compositions and methods for diagnosing, monitoring, staging, imaging and treating stomach cancer
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US6573048B1 (en) 2000-04-18 2003-06-03 Naxcor Degradable nucleic acid probes and nucleic acid detection methods
EP1366366B1 (en) 2000-05-10 2010-10-20 Signe BioPharma Inc. Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
EP1289565B1 (en) 2000-06-02 2015-04-22 Bracco Suisse SA Compounds for targeting endothelial cells
AU2001270164A1 (en) 2000-06-26 2002-01-08 The United States Of America As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
AU2001289617A1 (en) 2000-06-30 2002-01-08 Epigenomics Ag Diagnosis of diseases associated with signal transduction
US6596490B2 (en) 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
WO2002010169A1 (en) 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
US6797471B2 (en) 2000-08-04 2004-09-28 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers
JP2002067789A (ja) * 2000-09-05 2002-03-08 Yazaki Corp ランプユニットの電線接続構造
US20030031678A1 (en) 2000-09-19 2003-02-13 Shujath Ali Compositions and methods relating to prostate specific genes and proteins
US20030082604A1 (en) 2000-09-27 2003-05-01 Swanson Melvin J. High density arrays
US6617112B2 (en) 2000-10-11 2003-09-09 Monsanto Technology Llc Methods for gene array analysis of nuclear runoff transcripts
US7162371B1 (en) 2000-10-11 2007-01-09 Georgia Tech Research Corporation Differentially-expressed conifer cDNAs, and their use in improving somatic embryogenesis
US6350580B1 (en) 2000-10-11 2002-02-26 Stratagene Methods for detection of a target nucleic acid using a probe comprising secondary structure
WO2002032396A2 (en) 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
WO2002048168A1 (en) * 2000-10-24 2002-06-20 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression
US7001724B1 (en) 2000-11-28 2006-02-21 Applera Corporation Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
ES2445748T3 (es) 2000-12-04 2014-03-05 Primagen B.V. Ensayos basados en ácidos nucleicos de orgánulos celulares endosimbiontes
US20030099976A1 (en) 2001-01-17 2003-05-29 Tai-Jay Chang Androgen receptor complex-associated protein
US20040115671A1 (en) 2001-01-18 2004-06-17 Zlokovic Berislav V Gene expression profiling of endothelium in alzheimer's disease
US7015047B2 (en) 2001-01-26 2006-03-21 Aviva Biosciences Corporation Microdevices having a preferential axis of magnetization and uses thereof
WO2002064835A2 (en) 2001-01-31 2002-08-22 Ambion, Inc. Methods for nucleic acid fingerprint analysis
US20040110191A1 (en) 2001-01-31 2004-06-10 Winkler Matthew M. Comparative analysis of nucleic acids using population tagging
US20040058373A1 (en) 2001-01-31 2004-03-25 Winkler Matthew M. Competitive amplification of fractionated targets from multiple nucleic acid samples
WO2002073504A1 (en) 2001-03-14 2002-09-19 Gene Logic, Inc. A system and method for retrieving and using gene expression data from multiple sources
US20030170623A1 (en) 2001-04-13 2003-09-11 Jingwen Chen Multiplexed gene analysis on a mobile solid support
EP1390387A4 (en) 2001-04-20 2004-12-08 Ludwig Inst Cancer Res CANCER AND TESTICLE ANTIGENS
US20050065333A1 (en) 2001-04-27 2005-03-24 Arun Seth Breast cancer-associated genes and uses thereof
CA2445947A1 (en) 2001-04-30 2002-11-07 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
AUPR480901A0 (en) 2001-05-04 2001-05-31 Genomics Research Partners Pty Ltd Diagnostic method for assessing a condition of a performance animal
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040243362A1 (en) 2001-06-01 2004-12-02 Liebman Michael N. Information processing method for disease stratification and assessment of disease progressing
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040086504A1 (en) 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
WO2003001335A2 (en) 2001-06-22 2003-01-03 Gene Logic, Inc. Platform for management and mining of genomic data
AU2002346008A1 (en) 2001-06-28 2003-03-03 Dermtech International Method for detection of melanoma
EP1406653A4 (en) 2001-06-29 2005-05-04 Univ Leland Stanford Junior T-LYMPHOCYTE REGULATORY GENES AND METHODS OF USE
US20030143571A1 (en) 2001-08-08 2003-07-31 North Carolina State University Infectious disease microarray
AU2002331777A1 (en) 2001-08-30 2003-03-18 Spectral Genomics, Inc. Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7078180B2 (en) 2001-09-05 2006-07-18 The Children's Hospital Of Philadelphia Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
EP1423542A2 (en) 2001-09-06 2004-06-02 MERCK PATENT GmbH Genetic analysis of biological samples in arrayed expanded representations of their nucleic acids
EP1425090A2 (en) 2001-09-07 2004-06-09 Corning Incorporated MICROCOLUMN−PLATFORM BASED ARRAY FOR HIGH−THROUGHPUT ANALYSIS
AU2002341752B2 (en) 2001-09-19 2008-04-03 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
AU2002305767B2 (en) 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
US6593091B2 (en) 2001-09-24 2003-07-15 Beckman Coulter, Inc. Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
EP1434883A2 (en) 2001-10-02 2004-07-07 Azign Bioscience A/S Specific differential display arrays
CA2463725A1 (en) 2001-10-12 2003-11-06 Spectral Genomics, Inc. Compilations of nucleic acids and arrays and methods of using them
WO2003040410A1 (en) 2001-11-02 2003-05-15 Nimblegen Systems, Inc. Detection of hybridization oligonucleotide microarray through covalently labeling microarray probe
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
US20050095646A1 (en) 2001-11-19 2005-05-05 Sherman Michael I. Method of using a non-antibody protein to detect and measure an analyte
DE60228995D1 (de) 2001-12-19 2008-10-30 Affymetrix Inc Arrayplatten und verfahren zur herstellung von arrayplatten
CA2469480A1 (en) 2001-12-27 2003-07-17 Agy Therapeutics, Inc. Use of biomolecular targets in the treatment and visualization of tumors
US7141372B2 (en) 2002-01-18 2006-11-28 Health Research Incorporated Universal RT-coupled PCR method for the specific amplification of mRNA
EP1470255A2 (en) 2002-01-30 2004-10-27 Epigenomics AG Identification of cell differentiation states based on methylation patterns
CA2474530A1 (en) 2002-02-07 2003-08-14 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Diagnostic microarray and method of use thereof
US20030232356A1 (en) 2002-02-08 2003-12-18 Dooley Thomas P. Skin cell biomarkers and methods for identifying biomarkers using nucleic acid microarrays
EP1448590A4 (en) * 2002-02-20 2004-12-15 Sirna Therapeutics Inc INHIBITION INDUCED BY THE INTERFERENCE OF RNA OF THE MYC AND MYB GENES OR OF GENES INTERVENING IN THEIR RESPECTIVE PATHWAYS
WO2003076928A1 (en) 2002-03-07 2003-09-18 University Of Utah Research Foundation Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis
JP2005521420A (ja) 2002-04-03 2005-07-21 エージーワイ セラピューティクス インコーポレイティッド 脳腫瘍の処置及び可視化における生体分子標的の使用法
US20070025997A1 (en) 2002-04-03 2007-02-01 Usha Nagavarapu Use of biomolecular targets in the treatment and visualization of brain tumors
ES2465574T3 (es) 2002-05-03 2014-06-06 Duke University Un método para regular la expresión génica
DE60323625D1 (de) 2002-05-03 2008-10-30 Vialogy Llc Verfahren zur charakterisierung der ausgangssignale eines microarrays
KR20050037991A (ko) 2002-05-20 2005-04-25 노드롭 그루만 코포레이션 자동 오염원 생물학적 병원체 검출시스템
JP4544989B2 (ja) 2002-05-24 2010-09-15 ニンブルゲン システムズ インコーポレイテッド 単一マイクロアレイ上で多数の試料のハイブリダイゼーション反応を行うマイクロアレイ及びその方法
AUPS261402A0 (en) 2002-05-28 2002-06-20 Compusign Pty Ltd Array monitoring
US20030228579A1 (en) 2002-06-05 2003-12-11 Uri Alon Ordering genes by analysis of expression kinetics
EP1527176B2 (en) 2002-08-05 2017-03-22 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
WO2004014933A1 (en) * 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US20040029128A1 (en) 2002-08-08 2004-02-12 Epigenomics, Inc. Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
US20040029121A1 (en) 2002-08-08 2004-02-12 Susan Cottrell Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
AU2003268105B2 (en) 2002-08-16 2011-11-03 John Wayne Cancer Institute Molecular lymphatic mapping of sentinel lymph nodes
WO2004025556A2 (en) 2002-09-12 2004-03-25 Baylor College Of Medecine System and method for image segmentation
AU2003267583A1 (en) 2002-09-19 2004-04-08 The Chancellor, Master And Scholars Of The University Of Oxford Molecular arrays and single molecule detection
AU2003282877B9 (en) 2002-09-25 2011-05-12 University Of Massachusetts In Vivo gene silencing by chemically modified and stable siRNA
AU2003291287A1 (en) 2002-11-01 2004-06-07 John Fonda Crary Apkc isoforms in nervous system disorders and cancer
EP1418241A1 (en) 2002-11-08 2004-05-12 PrimaGen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
ATE546528T1 (de) 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20040175732A1 (en) * 2002-11-15 2004-09-09 Rana Tariq M. Identification of micrornas and their targets
AU2003295539A1 (en) 2002-11-15 2004-06-15 University Of Massachusetts Allele-targeted rna interference
WO2004050125A1 (ja) 2002-12-03 2004-06-17 Koken Co.,Ltd. 腫瘍細胞の増殖及び／又は浸潤の抑制剤
US7851150B2 (en) 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
JP4230457B2 (ja) * 2002-12-18 2009-02-25 サード・ウェーブ・テクノロジーズ・インク 低分子核酸の検出方法
CN101061236A (zh) 2003-01-13 2007-10-24 艾默瑞大学 在正常细胞和癌细胞中检测基因表达的方法
CN1761756B (zh) 2003-01-16 2013-03-13 北卡罗来纳州大学 禽类物种中内源性原生殖细胞的耗减
WO2004066183A2 (en) * 2003-01-22 2004-08-05 European Molecular Biology Laboratory Microrna
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20060247193A1 (en) 2003-02-10 2006-11-02 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US20040224337A1 (en) 2003-03-04 2004-11-11 Erik Foehr Use of biomolecular targets in the treatment and visualization of tumors
US20050164212A1 (en) * 2003-03-06 2005-07-28 Todd Hauser Modulation of gene expression using DNA-RNA hybrids
US20050112604A1 (en) 2003-03-14 2005-05-26 Akihide Fujimoto Loss of heterozygosity of the DNA markers in the 12q22-23 region
US7718364B2 (en) 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
WO2004090105A2 (en) * 2003-04-02 2004-10-21 Dharmacon, Inc. Modified polynucleotides for use in rna interference
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
AU2004227414A1 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals iRNA conjugates
US20040229211A1 (en) 2003-05-13 2004-11-18 Yeung Wah Hin Alex Sensitive diagnostic testing methodology using multiplex real time PCR with one dye (MOD) and its use as in severe acute respiratory syndrome (SARS)
WO2004105573A2 (en) 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
ATE485394T1 (de) 2003-06-02 2010-11-15 Univ Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
EP3502252B1 (en) 2003-06-02 2023-04-05 University of Massachusetts Methods and compositions for controlling efficacy of rna silencing
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
CA2533701A1 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US20050037362A1 (en) 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
US20060183128A1 (en) 2003-08-12 2006-08-17 Epigenomics Ag Methods and compositions for differentiating tissues for cell types using epigenetic markers
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
EA009376B1 (ru) 2003-11-10 2007-12-28 Нокссон Фарма Аг Нуклеиновые кислоты, специфично связывающие биоактивный грелин
US20050130170A1 (en) 2003-12-16 2005-06-16 Jeanne Harvey Identification and verification of methylation marker sequences
US20050130172A1 (en) 2003-12-16 2005-06-16 Bayer Corporation Identification and verification of methylation marker sequences
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
CA2556435C (en) * 2004-02-13 2014-08-12 The Rockefeller University Anti-microrna oligonucleotide molecules
KR100522307B1 (ko) * 2004-02-19 2005-10-19 변영철 화장용브러시
US7402389B2 (en) 2004-02-24 2008-07-22 The Translational Genomics Research Institute (Tgen) Compositions and methods for prognosis of cancers
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
JP2007530679A (ja) 2004-03-27 2007-11-01 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ 癌治療のための組成物および方法
US20060134639A1 (en) 2004-04-06 2006-06-22 Huffel Christophe V Method for the determination of cellular transcriptional regulation
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
CN101056991A (zh) 2004-04-20 2007-10-17 基因耐克生物医学制品有限公司 检测ncRNA的方法
EP1747023B2 (en) 2004-05-04 2016-03-09 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for reducing hcv viral genome amounts in a target cell
AU2005243410B2 (en) 2004-05-14 2010-04-22 Rosetta Genomics Ltd. Micronas and uses thereof
WO2005116261A2 (en) 2004-05-24 2005-12-08 Albert Einstein College Of Medecine Of Yeshiva University Rna expression microarrays
JP5435864B2 (ja) 2004-05-28 2014-03-05 アシュラジェン インコーポレイテッド マイクロｒｎａに関与する方法および組成物
US7575863B2 (en) 2004-05-28 2009-08-18 Applied Biosystems, Llc Methods, compositions, and kits comprising linker probes for quantifying polynucleotides
US20050287539A1 (en) 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
US7579451B2 (en) 2004-07-21 2009-08-25 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
JP2008511678A (ja) 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
US20060057595A1 (en) 2004-09-16 2006-03-16 Applera Corporation Compositions, methods, and kits for identifying and quantitating small RNA molecules
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US7592441B2 (en) 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
US20090186353A1 (en) 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
US7642348B2 (en) 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
US20060078894A1 (en) 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
EP1812596A4 (en) 2004-10-12 2010-07-14 Wayne John Cancer Inst TREATMENT OF CANCER AND COMPOSITIONS
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
DK2302055T3 (da) 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
US7074622B2 (en) 2004-11-15 2006-07-11 Eastman Kodak Company Method and system for sorting and separating particles
EP1831684A4 (en) 2004-11-30 2009-03-11 Veridex Llc PROGNOSTICS OF LUNG CANCER
US20060154275A1 (en) 2004-12-02 2006-07-13 The Board Of Trustees Of The Leland Stanford Junior University Regulated genes in cervical cancer
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
EP1863516A2 (en) 2005-02-08 2007-12-12 Board of Regents, The University of Texas System Compositions and methods involving mda-7 for the treatment of cancer
US7495073B2 (en) 2005-03-24 2009-02-24 Asia Hepato Gene Company Short isoform of Annexin A10 at chromosome 4q, termed Annexin 10s (ANXA10s) and methods of use
US20090062184A1 (en) 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
GB2425311A (en) * 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
EP1874793A4 (en) 2005-04-15 2008-12-24 Univ Texas DISTRIBUTION OF SIRNA BY NEUTRAL LIPID COMPOSITIONS
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070072201A1 (en) * 2005-05-16 2007-03-29 Kohne David E Method for producing improved nucleic acid oligomer functional homogeneity and functional characteristic information and results and oligomer application results
US20060265771A1 (en) * 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
GB0601102D0 (en) 2006-01-19 2006-03-01 Nuclea Biomarkers Llc Kinase Peptides And Antibodies
US20070054287A1 (en) 2005-05-31 2007-03-08 Applera Corporation Method for identifying medically important cell populations using micro rna as tissue specific biomarkers
EP1904110A4 (en) 2005-06-03 2009-02-11 Southern Adelaide Health Servi TARGETING CELLS HAVING A MODIFIED EXPRESSION MICROARN
US20070065844A1 (en) 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
CA2611507A1 (en) 2005-06-09 2006-12-21 Epoch Biosciences, Inc. Improved primer-based amplification methods
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
KR101140575B1 (ko) * 2005-06-30 2012-05-02 엘지디스플레이 주식회사 액정표시장치 검사공정
JP5489459B2 (ja) 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
IL177006A0 (en) 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070041934A1 (en) 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
WO2007033023A2 (en) 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
JP2009514874A (ja) 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Ｓａｈａ及びペメトレキセドを用いて癌を治療する方法
US7390792B2 (en) 2005-12-15 2008-06-24 Board Of Regents, The University Of Texas System MicroRNA1 therapies
US8288354B2 (en) 2005-12-28 2012-10-16 The Scripps Research Institute Natural antisense and non-coding RNA transcripts as drug targets
WO2007073737A1 (en) 2005-12-29 2007-07-05 Exiqon A/S Detection of tissue origin of cancer
ES2465600T3 (es) 2006-01-05 2014-06-06 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos del páncreas
ES2554531T3 (es) 2006-01-05 2015-12-21 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
EP2586454B1 (en) 2006-01-05 2014-10-08 The Ohio State University Research Foundation MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
US20070259827A1 (en) 2006-01-25 2007-11-08 University Of Massachusetts Compositions and methods for enhancing discriminatory RNA interference
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
CA2638844C (en) 2006-03-02 2016-05-03 Thomas D. Schmittgen Microrna expression profile associated with pancreatic cancer
US7955848B2 (en) 2006-04-03 2011-06-07 Trustees Of Dartmouth College MicroRNA biomarkers for human breast and lung cancer
CA2655355C (en) 2006-06-16 2014-05-06 Taisho Pharmaceutical Co., Ltd. Use of rpn2 gene expression inhibitor
US20080076674A1 (en) 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
CN101657547B (zh) 2006-07-13 2016-04-27 俄亥俄州立大学研究基金会 用于诊断和治疗结肠癌相关疾病的基于微小rna的方法和组合物
WO2008014008A2 (en) 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008036741A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
CA2663962A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2115138A2 (en) 2006-09-19 2009-11-11 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
US20080131878A1 (en) 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
CN101627121A (zh) 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
EP2104737B1 (en) 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
EP2104734A2 (en) 2006-12-08 2009-09-30 Asuragen, INC. Mir-20 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008088858A2 (en) 2007-01-17 2008-07-24 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
EP2124967A4 (en) 2007-01-26 2011-01-05 Rosetta Genomics Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF HEMATOPOIETIC MALIGNOMES
WO2008095096A2 (en) 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
US8741283B2 (en) 2007-04-20 2014-06-03 Sigma-Tau Rare Diseases, S.A. Adenosine deaminase anticancer therapy
EP2142659A4 (en) 2007-04-30 2010-06-09 Univ Ohio State Res Found METHOD FOR THE DISTINCTION OF PANCREATIC CANCER OF NORMAL IMMERSION SPECTRUM FUNCTIONS AND CHRONIC IMMERSION IMAGING IGNITION
CA2686165A1 (en) * 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising mir34 therapeutic agents for treating cancer
US20090131354A1 (en) 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090227533A1 (en) 2007-06-08 2009-09-10 Bader Andreas G miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
US7993831B2 (en) 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
WO2009052386A1 (en) 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009058907A2 (en) 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20110009469A1 (en) * 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
WO2009086156A2 (en) 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
EP2260110B1 (en) 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
JP2011517932A (ja) 2008-02-28 2011-06-23 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション ヒト慢性リンパ球性白血病（ｃｃｌ）と関連するマイクロｒｎａシグネチャーおよびその使用
WO2009111643A2 (en) 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
US8404659B2 (en) * 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
WO2009154835A2 (en) 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009126726A1 (en) 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
EP2285960B1 (en) 2008-05-08 2015-07-08 Asuragen, INC. Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis
US8900627B2 (en) 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
US20100090959A1 (en) 2008-10-14 2010-04-15 Sony Ericsson Mobile Communications Ab Forming a keyboard from a combination of keys displayed on a touch sensitive display and on a separate keypad
US20100179213A1 (en) 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
WO2010084488A1 (en) * 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
US7665785B1 (en) 2009-04-08 2010-02-23 Newton Paul A Column pipe catch tool
WO2011050129A1 (en) * 2009-10-21 2011-04-28 Trustees Of Dartmouth College Microrna-10 antagonists and microrna-10 targets for use in the treatment of a glioma
US8841273B2 (en) 2009-10-28 2014-09-23 Board Of Regents, The University Of Texas System Methods and compositions for anti-EGFR treatment
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
JP2013511559A (ja) 2009-11-24 2013-04-04 ザ ユニバーシティ オブ ウェスタン オーストラリア 上皮成長因子受容体リガンドのモジュレーション
US8846631B2 (en) 2010-01-14 2014-09-30 Regulus Therapeutics Inc. MicroRNA compositions and methods
US8933051B2 (en) 2010-09-30 2015-01-13 University Of Zurich Treatment of B-cell lymphoma with microRNA
WO2012106591A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
WO2012106586A1 (en) * 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-124
US8785709B2 (en) 2011-03-30 2014-07-22 University Of Louisville Research Foundation, Inc. Catalytic isomerisation of linear olefinic hydrocarbons
UA115652C2 (uk) 2011-04-25 2017-12-11 Реґюлус Терап'Ютікс Інк. Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
JP2015501645A (ja) 2011-12-10 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション 肺がんの腫瘍発生および化学療法耐性を低減するために有用なｍｉＲＮＡならびに関連する組成物および方法
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
EP2968567A2 (en) 2013-03-15 2016-01-20 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
AU2014302702A1 (en) 2013-06-24 2015-12-17 Mirna Therapeutics, Inc. Biomarkers of miR-34 activity
EP3126496A1 (en) 2014-04-01 2017-02-08 Mirna Therapeutics, Inc. Microrna dosing regimens

Also Published As

Publication number Publication date
EP2314688A1 (en) 2011-04-27
EP1838852A2 (en) 2007-10-03
US9068219B2 (en) 2015-06-30
US20120065248A1 (en) 2012-03-15
US20130303591A1 (en) 2013-11-14
EP2284265B1 (en) 2015-01-07
CA2857901A1 (en) 2006-12-28
JP5620556B2 (ja) 2014-11-05
EP2284265A1 (en) 2011-02-16
US20080050744A1 (en) 2008-02-28
JP2014223080A (ja) 2014-12-04
ES2503740T3 (es) 2014-10-07
EP2287303A1 (en) 2011-02-23
PL2302055T3 (pl) 2015-02-27
US8173611B2 (en) 2012-05-08
US20140348907A1 (en) 2014-11-27
EP2808389A1 (en) 2014-12-03
EP2302052A1 (en) 2011-03-30
US8563708B2 (en) 2013-10-22
US20080171715A1 (en) 2008-07-17
US20150344883A1 (en) 2015-12-03
ES2503765T3 (es) 2014-10-07
US20170037404A1 (en) 2017-02-09
US20080176766A1 (en) 2008-07-24
EP2287303B1 (en) 2014-07-02
EP2298894B1 (en) 2014-07-16
AU2005333165B2 (en) 2012-07-19
JP2010178741A (ja) 2010-08-19
US7960359B2 (en) 2011-06-14
US8765709B2 (en) 2014-07-01
EP2302056A1 (en) 2011-03-30
EP2292755A1 (en) 2011-03-09
EP2281889A1 (en) 2011-02-09
ES2503741T3 (es) 2014-10-07
EP2322616A1 (en) 2011-05-18
JP2014217384A (ja) 2014-11-20
EP2292756B1 (en) 2014-07-16
ES2503738T3 (es) 2014-10-07
EP2298894A1 (en) 2011-03-23
EP2281887A1 (en) 2011-02-09
EP2302055A1 (en) 2011-03-30
US20140314833A1 (en) 2014-10-23
US8946177B2 (en) 2015-02-03
US20140350086A1 (en) 2014-11-27
US20150352046A1 (en) 2015-12-10
US20110313025A1 (en) 2011-12-22
EP2281888A1 (en) 2011-02-09
JP2014217381A (ja) 2014-11-20
US9506061B2 (en) 2016-11-29
JP2008519606A (ja) 2008-06-12
EP2302054B1 (en) 2014-07-16
EP2281888B1 (en) 2015-01-07
ES2507544T3 (es) 2014-10-15
DK2302055T3 (da) 2014-10-13
US20150275213A1 (en) 2015-10-01
JP2014217385A (ja) 2014-11-20
EP2302051A1 (en) 2011-03-30
US20130143945A1 (en) 2013-06-06
JP2016165292A (ja) 2016-09-15
EP2298893A1 (en) 2011-03-23
US20140031415A1 (en) 2014-01-30
JP5389690B2 (ja) 2014-01-15
CA2850323A1 (en) 2006-12-28
US20150004221A1 (en) 2015-01-01
EP2302055B1 (en) 2014-08-27
US8058250B2 (en) 2011-11-15
US20150361431A1 (en) 2015-12-17
JP2014012020A (ja) 2014-01-23
US20150005366A1 (en) 2015-01-01
WO2006137941A2 (en) 2006-12-28
HK1204656A1 (en) 2015-11-27
US20150344881A1 (en) 2015-12-03
EP2281886B1 (en) 2014-07-16
ES2503743T3 (es) 2014-10-07
EP2302054A1 (en) 2011-03-30
EP2281886A1 (en) 2011-02-09
EP2302056B1 (en) 2015-01-07
US20150284720A1 (en) 2015-10-08
US9447414B2 (en) 2016-09-20
EP2292756A1 (en) 2011-03-09
EP2302053A1 (en) 2011-03-30
US9051571B2 (en) 2015-06-09
JP2014217386A (ja) 2014-11-20
US20150284719A1 (en) 2015-10-08
ES2534301T3 (es) 2015-04-21
CA2857881A1 (en) 2006-12-28
EP2808390A1 (en) 2014-12-03
ES2534302T3 (es) 2015-04-21
EP2302051B1 (en) 2015-01-07
WO2006137941A9 (en) 2007-03-08
CA2857878A1 (en) 2006-12-28
US20140348908A1 (en) 2014-11-27
ES2503742T3 (es) 2014-10-07
US20150342981A1 (en) 2015-12-03
JP2014217387A (ja) 2014-11-20
JP5596085B2 (ja) 2014-09-24
ES2534304T3 (es) 2015-04-21
CA2857879A1 (en) 2006-12-28
EP2314688B1 (en) 2014-07-16
US9382537B2 (en) 2016-07-05
AU2005333165A1 (en) 2006-12-28
JP2012228254A (ja) 2012-11-22
US20150299705A1 (en) 2015-10-22
WO2006137941A3 (en) 2008-01-03
SI2302055T1 (sl) 2015-01-30
US20090176723A1 (en) 2009-07-09
CA2857880A1 (en) 2006-12-28
CA2587189A1 (en) 2006-12-28
EP2281889B1 (en) 2014-07-30
EP2302052B1 (en) 2015-01-07
ES2534300T3 (es) 2015-04-21
ES2534303T3 (es) 2015-04-21

Similar Documents

Publication Publication Date Title
ES2503739T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
JP2010539959A5 (es)
US9284554B2 (en) Micro-RNA scaffolds and non-naturally occurring micro-RNAs
JP5902088B2 (ja) マイクロｒｎａの製造方法およびその治療的応用
US11041201B2 (en) Methods for detection of RNase activity
US20110151430A1 (en) VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION
JP2020536554A5 (es)
CN103476947A (zh) 寡聚体的增强的生物分布
US8859239B2 (en) Methods for small RNA sequencing
NM_205822 et al. Supplementary Table
WO2024104396A1 (zh) 一种使用miRNA亚型相对家族占比检测癌症等疾病的方法
Omnibus AUC: area under curve. KEGG: Kyoto Encyclopedia of Genes and Genomes. GEO: Gene
Name_ID SUPPLEMENTARY TABLE
LUAD 17 hsa-mir-222 88.23 Table S1: List of miRNAs returned from at least one run of the DE algorithm. The list is sorted according to decreasing number of times it has been reported. The value of the k-esim row refears to the classification accuracy obtained using the subset of the first k miRNAs.